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As with most new procedures, the intra-arterial infu¬ 
sion of vasopressin for the control of gastro-intestinal 
bleeding does entail certain risks. Among these has been 
the fear that hepatic ischemia may result secondary to de¬ 
creased hepatic artery blood flow if the hepatic artery 
were to be directly exposed to vasopressin during celiac 
axis or superior mesenteric artery infusions. (9;106;132;173) 
Using the dog as my experimental model I have studied 
the changes in blood flow through the hepatic artery with 
non-cannulating electromagnetic flow probes during the 
direct intra-celiac infusion of vasopressin. I then exa¬ 
mined the pre- and post-infusion angiograms of patients 
who underwent therapeutic intra-celiac vasopressin infusion 
for gastro-intestinal bleeding at the West Haven Veterans' 
Administration Hospital to correlate the results which I 
found in the laboratory in dogs with actual clinical ob¬ 




In order to fully understand both my laboratory work 
and its clinical significance it would be useful for the 
reader to be knowledgeable about vasopressin, the hepatic 
vasculature, and angiography, as well as having a clear 
understanding of the pertinent experiments which comprise 
the background against which my results must be interpreted 
and evaluated. I have attempted to provide this informa¬ 
tion in the following sections. 
VASOPRESSIN 
Vasopressin is synthesized in cell bodies in the para¬ 
ventricular and supraoptic nuclei o’f the hypothalamus and 
migrates along the axons of these nerve cells to be stored 
as neurosecretory granules in the nerve cell endings near 
perivascular spaces in the neurohypophysis, which is part 
of the posterior lobe of the pituitary gland formed as a 
downward growth from the floor of the diencephalon. Oxyto¬ 
cin, which causes contraction of uterine muscle and contrac¬ 
tion of myoepithelial cells in the alveoli of mammary glands 
is also synthesized and stored by an identical hypothalamo- 
posterior hypophyseal system. (19;45) The control of 
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vasopressin release is mediated through osmoreceptors 
(increased plasma osmolarity leads to increased vasopressin 
release),(95) volume receptors (increased plasma volume 
leads to decreased vasopressin release), (76) as well as 
by emotional and physical stress. (95) 
Oliver first demonstrated the pressor effect of pit¬ 
uitary extract in 1895, noting that intravenous infusion 
of the extract caused a rise in blood pressure and that 
perfusion of the extract through the vascular system of a 
pithed frog greatly decreased the flow of fluid. (137) 
In 1928, Kamm separated two active principles from the 
posterior pituitary; one was a pure pressor principle 
eighty times as potent as the International Standard of 
Powdered Pituitary and the other was a pure oxytocic prin¬ 
ciple. He found the pressor principle to also be respon¬ 
sible for the anti-diuretic action of pituitary extract 
(96) which had first been described by von den Velden in 
1913. (190) In 1953, DuVigneaud identified and synthesized 
arginine-8-vasopressin (62) which is the natural ocurring 
hormone in all mammals except for the pig and the hippopot¬ 
amus, where arginine in the side chain is replaced by lysine 
to form lysine vasopressin. The vasopressins are all cyclic 
octapeptides with a closed ring of five amino acids and a 
side chaiir of three amino acids. (182) The chemical activity 
of the compound depends on both the cyclic pentapeptide and 
the tripeptide side chain; thus, opening of the circle or 
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removal of the terminal glycine amine group (by trypsin, for 
example) rapidly inactivates the vasopressin. (76) 
The third common type of vasopressin available in 
addition to the lysine-8-vasopressin and arginine-8-vaso- 
pressin is phenylalanine-lysine-vasopressin (PLV-2) a syn¬ 
thetic compound formed by substituting phenylalanine for 
tyrosine in position two of lysine vasopressin. Phenylal¬ 
anine-lysine-vasopressin has been found to have the same 
pressor effect as the natural occurring vasopressins, but 
anywhere from 1/2 to 1/70 their anti-diuretic effect; PLV-2 
is, therefore, felt to have a selective pressor effect. 
(15;182) Lysine and arginine vasopressins have equivalent 
pressor and anti-diuretic effects when compared with each 
other. 
Although we are mainly concerned with the effect of 
vasopressin on the gastro-intestinal vasculature, we should 
briefly review some of its other properties. The main effect 
of vasopressin is to control the reabsorption of free water 
from the collecting tubules of the kidney. This is achieved 
by vasopressin doses many hundreds of times smaller than 
those doses required to produce a pressor response (47), 
and it is probably the only true physiologic function of 
vasopressin in mammals. (76) In pharmacologic doses, how¬ 
ever, vasopressin has many additional effects. In 1930, 
Gruber and Kountz, and in 1961, Drapanas, found that vaso- 
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pressin caused constriction of the coronary arteries (26; 
53;85) in addition to a decreased heart rate and increased 
systemic arterial blood pressure. The fall in heart rate 
was only partially prevented by severing of the vagi or 
administration of atropine and, therefore, it was felt to 
be due to both a parasympathetic response to the increased 
blood pressure as well as a direct depressive effect of 
vasopressin on the myocardium. (85) Vasopressin was also 
noted to cause Cheynes-Stokes respirations in unanesthetized 
dogs. (84) Vasopressin is known to decrease the basal 
metabolism rate, cardiac oxygen consumption, and the car¬ 
diac output in mammals. (46;50;53;63;71;187) The decrease 
in cardiac output is associated with a decrease in cardiac 
work and is probably due to a direct depressive effect of 
vasopressin on the myocardium in addition to the decrease 
in coronary blood flow and the reflex bradycardia. (63) 
In 1898, Von Cyan first reported pulsus bigeminus in ani¬ 
mals injected with pituitary extract (85); since then vaso¬ 
pressin has been noted to cause several EKG changes includ¬ 
ing prolonged P-R interval, sino-atrial block, non-specific 
ST-T wave changes, and various irregular rhythms. (155) 
Ruskin has suggested using vasopressin as a test to bring 
out latent coronary vascular insufficiency; using anginal 
pain following vasopressin injection as his end point he ob¬ 
tained results which correlated well with the Master's ex- 
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ercise test. (155) In 1936, Collins and Root reported on 
the use of vasopressin to eliminate intestinal gas during 
cholecystography; vasopressin (5-20 Units) increased the 
peristaltic activity and propulsive movement of the bowel. 
(76) There have been reports, however, of patients with no 
known EKG or clinical history of cardiac disease who have 
suffered acute and fatal myocardial infarctions during this 
procedure. (124;172) Dearing and Essex in 1944, by repeat¬ 
ed injections of vasopressin in cats, were able to produce 
focal histologic changes in the myocardium, most prominent 
in the sub-endocardial layers of muscle of the left ventricle, 
associated with significant EKG changes. (124) Due to its 
effect on gastro-intestinal motility vasopressin has also 
been used to relieve intestinal distention. (26) Vasopressin 
also reduces the volume of salivary, biliary and pancreatic 
juices (157) as well as reducing the volume of histamine, 
insulin, and food stimulated gastric secretions. (109;152; 
158;159) An initial and transient increase in blood flow 
through cutaneous vessels, secondary to increased systemic 
blood pressure and active vasodilatation of the vessels, 
is followed by a prolonged cutaneous vasoconstriction during 
vasopressin infusions. (35;192) Local infiltrations of 
vasopressin have been used in plastic, dental and cervical 
surgery to both prolong the effects of local anesthetics 
and to provide a bloodless field (104;140;168); vasopressin 
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was found to be superior to adrenaline for this purpose 
in that vasopressin produced pallor without the central 
cyanosis that was seen with adrenaline; it is therefore 
felt that adrenaline causes more tissue damage and necrosis 
with poorer healing. (100) Vasopressin has been found to 
exert a direct effect on the thyroid gland indentical with 
that of appropriate doses of TSH (69) as well as causing an 
increase in the level of serum cortisol felt to be medi¬ 
ated via the release of ACTH and not to be a direct effect 
on the adrenal cortex. (110;128) Both of these effects are 
only seen with exogenous pharmacologic levels of vasopressin. 
Vasopressin has also been found to protect pancreatic blood 
flow during experimental acute pancreatitis; when vasopressin 
was not given, pancreatic flow decreased by 40-60% but with 
vasopressin the pancreatic flow remained stable. This was 
attributed to the maintenance of good aortic perfusion pressure 
and to a redistribution of arterial flow within the pancreas 
to the areas of inflammation. (144) Finally, many of the above 
mentioned actions of vasopressin are manifested clinically 
during vasopressin infusions by skin pallor, abdominal cramps, 
nausea, bowel movements, and urgent micurition followed 
by several hours of anti-diuresis. (151;166;182) 
Vasopressin, in pharmacologic doses, also has signi¬ 
ficant effects upon the gastro-intestinal and hepatic vas¬ 
cular systems which make it useful in the treatment of 
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gastro-intestinal bleeds from both arterial and variceal 
sources. It is known that vasopressin causes peripheral 
vasoconstriction with a decrease in blood flow in the mus¬ 
cular arteries of the body, such as the branches of the fem¬ 
oral artery. (187) A similar effect is seen in the arteries 
supplying the gastro-intestinal system. Vasopressin has 
been shown to decrease the blood flow through the superior 
mesenteric artery by approximately 60%, (3;5;6;37;50;53; 
83;87;106;134;135;142;165) to decrease the inferior mes¬ 
enteric artery blood flow by equivalent amounts, (3;83;135; 
165) to decrease the splenic artery blood flow, (3;37;82; 
83;135;165) and to decrease the gastric artery blood flow 
by 20% to 70%. (3;14;25;50;135;142) The effect of vasopressin 
on the hepatic artery blood flow has been less clear, with 
several investigators reporting an increase in hepatic artery 
blood flow (3;37;63;83;87;90;135;141;169) while others report 
an increase in hepatic artery pressure and a decrease in 
hepatic artery blood flow as is seen in the rest of the 
systemic arteries in the body, (53;98;117;165) and still 
others report an inconsistent response of the hepatic artery 
to vasopressin. (142) I will discuss all of these experi¬ 
ments involving the hepatic artery in detail at the end of 
the introduction since they are directly related to my re¬ 
search . 
Vasopressin has also been found to be very effective 
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in lowering portal venous pressure in experimental animals 
as well as in man. (48;53;56;58;62;83;90;98;141;149;165; 
166;170;178;182) The predominant feeling is that this 
effect is secondary to a decrease in splenic, gastric, super¬ 
ior mesenteric and inferior mesenteric arterial blood flow 
secondary to vasoconstriction in these vessels so that as 
a result less blood is reaching the portal vein and thus 
a "medical" portal shunt is created; ie., the main effect 
of vasopressin on the portal vein seems to be pre-portal. 
(3;32;36;57;83;97;134;142;169;178) Several investigators, 
however, have claimed to demonstrate an additional direct 
response of the portal vein to vasopressin. (59;120;135; 
169) 
It is because of its arterial vasoconstrictive effects 
and its ability to reduce portal venous pressure that vaso¬ 
pressin has become a clinical tool in the treatment of 
gastro-intestinal bleeding. Vasopressin was first used to 
control hemorrhage during the first half of the twentieth 
century when it was used in intravenous doses of 10 units 
in & ten minute infusion to treat brisk hemoptysis secondary 
to bronchiectasis, tuberculosis, tumors, fungal diseases 
and so on. (181) The results were rather good, giving the 
clinician time to determine and treat the primary cause of 
the bleeding. Nevertheless, for reasons which are not 
perfectly clear this procedure is no longer used in the 
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treatment of severe hemoptysis. In 1955, Kehne reported on 
the successful use of intravenous vasopressin in the treat¬ 
ment of two patients with cirrhosis who were bleeding from 
esophageal varices. In both cases the bleeding was well con¬ 
trolled; the first patient re-bled five times over the next 
six months, responding well to vasopressin each time, and 
the second patient underwent excision of his varices and did 
well post-operatively. (98) There have been many other reports 
on the use of vasopressin in the control of hematemesis from 
esophageal varices since Kehne's original work. (43;122;132; 
133;153;162;166;182) It is felt by the above researchers that 
vasopressin controls the bleeding by reducing the portal venous 
pressure, thus either stopping, or at least decreasing the 
flow of blood through the esophageal varices so that a clot is 
able to form over the bleeding site. A possible additional 
mechanism, suggested by Aronsen, is that vasopressin actually 
causes constriction of the lower esophageal musculature. He 
created portal hypertension in dogs by ligating the portal vein 
fourteen of the animals developed porto-systemic communications 
in the form of para-esophageal and submucosal esophageal var¬ 
ices. During intravenous vasopressin infusion it was noted 
by angiography that the submucosal esophageal varices dis¬ 
appeared but the para-esophageal collaterals dilated; it was 
felt that this response was due to the contractile effect 
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of vasopressin on the smooth muscle of the esophageal wall, 
closing off the feeding and draining radicles of the sub¬ 
mucosal varices as they passed through the esophageal mus¬ 
culature and thereby causing more blood to flow through the 
para esophageal collaterals. (3) 
More recently Baum and Nusbaum, who were working with 
selective angiography to diagnose sites of gastro-intestinal 
bleeding (see angiography) infused vasopressin intra¬ 
arterially through the catheter which they had used for the 
angiographic demonstration of the bleeding site and which 
was still positioned in the bleeding vessel. They found 
that the direct infusion of vasopressin into a bleeding artery 
within the gastro-intestinal system led to cessation of 
bleeding from that vessel secondary to vasoconstriction and 
decreased blood flow, which then allowed the normal coagu¬ 
lation factors to function. They have successfully infused 
vasopressin into the superior mesenteric artery to control 
bleeding esophageal varices as well as small bowel ulcers. 
They have also infused vasopressin into the gastric artery 
to control Mallory Weiss tears, hemorrhagic gastritis and 
bleeding gastric ulcers; into the gastroduodenal artery to 
control bleeding duodenal ulcers, and into the hepatic artery 
to control a bleeding hepatoma. (9;11;47;130;132;133) Baum 
and Nusbaum have also used vasopressin intra-operatively 
to control blood loss during porta-caval shunt surgery. (9) 
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In general they have been able to control most bleeds where 
it was possible to infuse the vasopressin directly into the 
vessel which was bleeding, proximal to the site of bleeding. 
Vasopressin will not control bleeding secondary to erosion 
of the main stem of a major vessel; it is most effective when 
the bleeding site is from a peripheral branch of the artery 
since vasopressin is best at producing peripheral vasocon¬ 
striction. Baum and Nusbaum usually infuse vasopressin 
(Pitressin) at a dosage rate of 0.1-0.2 Pressor Units/cc./ 
minute; at these rates they claim to see no tachyphylaxis 
and only minimal cardiac and renal effects since most of 
the infused vasopressin is rapidly inactivated in the portal 
system. By infusing directly proximal to the bleeding site 
they are able to use much smaller doses than would be 
necessary with intravenous infusions. (191) 
Both Rosch and Meves, in different laboratories, infuse 
vasopressin into the superior mesenteric artery to control 
bleeding esophageal varices. However, for arterial gastro¬ 
intestinal bleeds they use epinephrine with propanolal in 
spite of the frequent occurrence of re-bound bleeding after 
the epinephrine infusions. (122;153) In comparing the vaso¬ 
pressin infusions with the epinephrine infusions Rosch found 
basically equivalent vasoconstrictor properties in the mes¬ 
enteric arteries, but post infusion blood flow in the epin¬ 
ephrine treated vessel was 145% of pre-infusion level for 
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three minutes while blood flow in the vasopressin treated 
vessel was still only 80% of pre-infusion level forty minutes 
after the infusion was ended. (154) 
Intra-arterial infusion of vasopressin is also being 
used to control bleeding from non-gastro-intestinal sites. 
Slezak reported infusing vasopressin into the internal iliac 
artery of a patient who was bleeding from a branch of that 
vessel which had been eroded away by carcinoma. He hypothe¬ 
sized that in addition to the vasoconstrictive effect of vaso¬ 
pressin, small clots may have embolized from the tip of the 
catheter and moved distally to occlude the bleeding site. 
He also emphasized the importance of careful fluid balance 
plus EKG and CVP monitoring to guard against cardiac and 
renal complications during vasopressin infusions. (171) 
The exact site of action of vasopressin on the gastro¬ 
intestinal vasculature is probably at the arteriolar level. 
Peter injected india ink into the gastric and superior mesen¬ 
teric arteries of dogs receiving vasopressin and found de^ 
creased capillary filling, implying that the constrictive 
effect is probably just proximal to the capillaries in small 
arterioles. (142) Texter, using pressure transducers connect¬ 
ed to various segments of the superior mesenteric artery 
found the greatest increase of vascular resistance and pressure 
during intra-arterial infusions of vasopressin to be local¬ 
ized to the small vessel segments of the superior mesenteric 
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artery. He found that vasopressin had no constrictive 
effect on the superior mesenteric vein and its branches. 
(178) Peskin injected small glass beads into the superior 
mesenteric artery and collected them in the portal vein to 
evaluate arterio-venous anastomoses in the small bowel. 
He noted a significant decrease in the number of beads re¬ 
trieved during the intravenous infusion of vasopressin and 
concluded that the arterio-venous shunts were closing down 
in response to the vasopressin. (141) Actually/ however, 
Peskin's results would also be consistent with arteriolar 
constriction proximal to the arterio-venous anastomoses. 
Delaney injected 20 micron'radioactive spheres into the 
superior mesenteric artery and recovered only 3% in the 
portal vein and liver. He assumed that this represented 
the amount of blood flowing through arterio-venous channels 
in the small bowel. Intravenous pitressin did not alter 
the percent of flow through the arterio-venous channels 
and he concluded that they were not the primary site of 
vasopressin's action. (49) Altura directly observed muscu¬ 
lar metarterioles (arterio-venous anastomoses) in the mesen- 
tary of a rat during topical vasopressin administration by 
using an image splitting television microscope recording 
system. He noted that the metarterioles did constrict when 
exposed to vasopressin, but the response was two to ten times 
less sensitive than the response of mesenteric arterioles 
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to topical vasopressin. (1) Thus, it seems that the main 
constrictive effect of vasopressin is on the arterioles. 
We must also remember, however, that vasopressin causes 
contraction of the muscular layers of the gastro-intestinal 
tract and that the flow of blood in vessels passing through 
this muscular layer will be markedly decreased during the 
muscular contractions. (3;63) Although of secondary impor¬ 
tance to the arteriolar constriction, this latter effect also 
will reduce gastro-intestinal blood flow. 
On a more cellular level, however, the mechanism of 
vasopressin is still a mystery. Adrenalectomized dogs and 
dogs with sympathectomies from L-2 caudally still respond 
to vasopressin with a decrease in blood flow as monitored 
in the femoral artery. (71) Both Corliss and Ericsson have 
noted that vasopressin's effects in pharmacologic doses 
are antagonized by neither adrenergic blocking agents nor 
vascular denervation. (46;62) However, Gardiner found that 
in dogs with circulatorily isolated carotid sinuses, sever¬ 
ed vagi and complete lack of recordable splanchnic sympathetic 
tone there was no pressor response to physiologic levels of 
vasopressin (0.01 unit/kg.). In those animals with severed 
vagi but with good sympathetic tone there was an increased 
sensitivity to vasopressin. (70) This latter work suggests 
that at least at physiologic levels vasopressin does depend 
on an intact sympathetic system in order to exert its pressor 
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effect. Lewis and Reit found that pharmacologic doses of 
vasopressin (2 units/kg.) in cats were able to stimulate 
neither the superior cervical ganglion nor the adrenal 
medulla as monitored by movement of normal and denervated 
nictitating membranes respectively. (113) Hertting and 
Suko found that pharmacologic doses of vasopressin were 
unable to release labelled noradrenaline from sympath¬ 
etic nerve endings in the isolated cat spleen. (91) Finally, 
it has been shown that vasopressin does not change the acti¬ 
vity of post ganglionic sympathetic nerves of the celiac 
ganglion but that phenoxybenzamine and/or phentolamine will 
inhibit the pressor response of physiologic doses of vaso¬ 
pressin. (180) Thus, it seems that vasopressin's effect 
is not mediated through the sympathetic nervous system; 
however, it does seem that at least at physiologic doses 
the catecholamines themselves help to potentiate vaso¬ 
pressin's pressor effect. This is supported by the find¬ 
ing that non-pressor doses of vasopressin will potentiate 
the pressor effect of catecholamines. (7) This may all 
be mediated through the 3'5' cyclic AMP system which was 
shown by Orloff in 1962, to be involved with vasopressin's 
effect on water movement through the toad bladder. (76) 
Cyclic AMP is found in vascular tissue and it is known that 
catecholamines increase the level of cyclic AMP in many 
tissues. Possibly vasopressin and the catecholamines po- 
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tentiate each other’s effects by increasing the availability 
of cyclic AMP. 
There has been very little work concerning the interrela¬ 
tionship between vasopressin and electrolytes, (76) although 
it has been shown that magnesium sulfate will inhibit vasopressin 
induced constriction of the superior mesenteric artery. (112) 
The half life of vasopressin in man is approximately fif¬ 
teen minutes, being removed from the plasma and inactivated 
mainly during passage through the liver and kidneys. (76) The 
initial passage of a pharmacologic dose of vasopressin through 
the liver is not sufficient to modify its pressor effects. (183) 
The mean half life of vasopressin in the dog is 5.4 minutes 
and over a broad range this does not seem to vary with the con¬ 
centration of vasopressin given, implying that the mechanism 
involved with vasopressin removal is not readily saturated.(108; 
167) In rats a total of 50% of an injected dose of vasopressin 
is cleared by the kidneys, but only 6-7% of the dose of vasopressin 
can be found in the urine, implying that approximately 90% of the 
vasopressin taken up by the kidneys is inactivated in the kidneys. 
The liver accounts for clearance of another 40% of the vasopressin 
given while the last 10% of vasopressin is cleared by other or¬ 
gans in the body.(75) Vasopressin is transported by the blood where 
it is confined to the plasma and is relatively free from any in¬ 
activation except in pregnant females who do have a vasopressinase 




Clark, in 1928, first noted that repeated injections 
of vasopressin had progressively diminishing pressor effects. 
(36) Razzak noted a similar tachyphylactic response; where¬ 
as an initial bolus of 3-5 units of vasopressin in dogs 
caused a 50% decrease in portal venous pressure the third 
bolus of vasopressin at twice the dosage caused only a 25% 
decrease in pressure. (149) Patil, however, suggested that 
we are not seeing true tachyphylaxis with vasopressin. 
Tachyphylaxis means a decreased response to repeated doses 
of a drug secondary to increased receptor saturation. Sev¬ 
eral drugs are able to offset the tachyphylactic effect of 
vasopressin: oubain does this by increasing cardiac output, 
ephedrine does it by inhibiting coronary vasoconstriction 
and reserpine does it by blocking reflexes. Methoxamine, 
which has no cardiotonic effects is unable to offset the 
tachyphylactic effect of vasopressin. Thus, Patil is 
suggesting that we are dealing with a "pseudo tachyphylaxis" 
due to cardiac fatigue rather than receptor saturation.(138) 
While the question is still not settled, Nusbaum noted no 
tachyphylaxis in patients receiving repeated doses of 0,1- 
0.2 units/minute of vasopressin for gastro-intestinal bleeds. 
(132) 
Finally, I would like to discuss some of the compli¬ 
cations of vasopressin therapy. It should be noted again 
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that all of the above mentioned effects of vasopressin are 
seen at pharmacologic doses; only the anti-diuretic effect 
is seen at physiologic levels. The complications and side 
effects of vasopressin therapy are actually the many diff¬ 
erent functions of vasopressin which were enumerated above. 
These include facial pallor, nausea, eructations, flatus, 
defecation and uterine cramps, all of which are readily 
controlled by decreasing the vasopressin dose. (76;151;166;182) 
More serious complications include mesenteric venous throm¬ 
bosis with bowel infarction (150), EKG changes, bradycardia, 
hypertension, anginal attacks, myocardial infarction and 
fluid retention. (26;124;172) Finally, several authors have 
warned of the potential hazard of hepatic ischemia and 
necrosis secondary to vasopressin's- effect on hepatic ar¬ 
tery blood flow. (9;132;173;106) Although I have been unable 
to find an actual reference in the literature of hepatic 
ischemia secondary to vasopressin infusion, Nusbaum, in 
answering a question in one of his most recent articles 
referred to a case of liver necrosis in a patient from 
Bellevue with portal hypertension who had received a vaso¬ 
pressin infusion for several days. Nusbaum hypothesized 
unrecognized occlusion of the celiac axis on the basis of 
arteriosclerotic disease so that the entire infusion of 
vasopressin went from the superior mesenteric artery through 
collaterals to the hepatic arterial system causing hepatic 
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ischemia and necrosis. (132) Baum and Nusbaum are especially 
cautious about infusing vasopressin into the hepatic artery: 
"If one of the branches of the hepatic artery arises from 
the superior mesenteric artery the tip of the catheter must 
be advanced beyond the origin of the hepatic artery in order 
to prevent a decrease in arterial blood flow to the liver" 
(9); "Care must be taken to avoid direct or indirect infusion 
of the hepatic artery" (9); "The celiac axis is not direct¬ 
ly infused due to the danger of hepatic necroses" (132). 
It is quotations such as the above which stimulated my in¬ 
terest in this research project, for if it could be estab¬ 
lished that vasopressin does not represent a threat to 
hepatic artery blood flow then it would follow that there 
is no danger of hepatic ischemia and necrosis during celiac 
infusions of vasopressin. This would be clinically signi¬ 
ficant in that celiac catheterization is much easier and 
quicker than super-selective catheterization of the left 
gastric, splenic, or gastro-duodenal arteries, and in a 
patient who is bleeding acutely this time factor is signi¬ 
ficant in the overall picture of therapeutic management 
and ultimate recovery. 
Before discussing my specific experiment, however, it 
is necessary to review what is known of the hepatic vascu¬ 
lar system, since only with this information will we be 
able to interpret my results and hypothesize about what 
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mechanisms might be responsible for what we are seeing. 
HEPATIC VASCULAR SYSTEM 
The liver is supplied by two afferent blood vessels, 
the hepatic artery and portal vein, which enter the liver 
at the hilum with the common bile duct. All three struc¬ 
tures branch together as they penetrate the liver mass, 
dividing into interlobar and then interlobular branches. 
It is well accepted by all observers that the portal vein 
then gives off smaller interlobular branches which finally 
send branches into the lobule where they subdivide to form 
a network of intralobular sinusoids. These sinusoids empty 
into the central vein of the lobule which feeds into the 
sublobular veins which eventually empty into one of the 
hepatic veins, which are the main efferent channels of the 
liver. The course of the hepatic artery branches is less 
clear. It is known that throughout its course the hepatic 
artery gives off a capillary network which supplies the ' 
hepatic connective tissue and the walls of the bile ducts. 
From this network venules enter the portal vein so that there 
is some pre-sinusoidal communication between the hepatic 
artery and portal vein (19;34), although the capillary net¬ 
work between the two vessels makes it unlikely that pressure 
or flow differences could be transmitted from one vessel 
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to the other at this level. The rest (and major part) of 
the arterial blood probably empties into the hepatic sinusoids 
via hepatic arterioles. (45;103) 
Although it is known that the portal vein supplies 
most of the hepatic blood flow, there has been some disagree¬ 
ment as to the total amount supplied by the hepatic artery. 
The following figures give an idea of the general range of 
hepatic artery contribution to total liver blood flow: 29.3± 
3.6% (73), 26-32% (116), 30% (27;28), 12.6-24.5% (17), 14%- 
50% with mean of 26% (160), 34% (164), 40% (74). The hepatic 
artery blood flow, however, varies with the systemic blood 
pressure. Thus, Herrick and Mann in 1938, found that the 
hepatic artery contributed 10-90% of total hepatic blood 
flow and Grayson found that at a systemic blood pressure 
of 110 mmHg in rats the hepatic artery contributed 50% of 
total blood flow, but at a systemic pressure of 80 mmHg the 
hepatic artery was responsible for 80% of total hepatic 
blood flow while at a systemic pressure of 130 mmHg the he¬ 
patic artery contributed only 30% of the flow. (80) This 
is probably due to autoregulation within the hepatic artery, 
enabling it to decrease its resistance when perfusion pressure 
is decreased thereby maintaining steady flow. The portal 
vein, however, is supplied by vessels which cannot autoreg- 
ulate, and therefore, when the systemic blood pressure is 
lowered the mesenteric, splenic and gastric arteries are 
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poorly perfused and as a result the portal venous flow drops 
so that the hepatic artery's relative contribution to total 
hepatic blood flow is increased. Conversly, when the per¬ 
fusion pressure of the hepatic artery is increased autoreg¬ 
ulation maintains hepatic artery blood flow at a fairly 
constant level by increasing the vascular resistance. The 
key to autoregulation is that blood flow and perfusion pressure 
are not a linear relationship. (23;41;88;175;176) The 
mechanism of hepatic artery autoregulation is probably a 
myogenic constriction in the vessel walls triggered by a 
rise in hepatic artery pressure; it is not dependent on 
innervation of the liver. (88) It seems that the portal 
vein lacks this ability.to maintain its flow by regulating 
its vascular resistance in the face of portal pressure 
changes, and thus, in the portal vein pressure and flow 
are a linear relationship and there is no autoregulation. 
(23;101;174;175) This will be discussed later in more detail 
in relation to reciprocal portal vein and hepatic artery 
flows. 
Although the hepatic artery supplies on the average only 
25% of the total liver blood flow it is responsible for 
32-100% of total hepatic oxygen uptake, with a mean value 
of 70%. (21;83) If the hepatic artery is constricted the 
oxygen content of the hepatic vein falls to less than one 
volume percent. (17) However, when the portal venous flow 
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is markedly reduced during vasopressin infusion the hepatic 
oxygen consumption is not decreased since the hepatic artery 
is able to maintain it at normal levels. (48) Also recall 
that the hepatic artery is responsible for the nutrition 
and oxygenation of the bile ducts and liver connective 
tissue so that a loss of hepatic arterial blood flow could 
be lethal secondary to necrosis of these basic liver struc¬ 
tures. (86) This is confirmed by experimental data. If the 
common hepatic artery of dogs is ligated proximal to its 
hepatic branches but distal to the right gastric artery 
(to eliminate most of the collateral circulation) all of 
the dogs die within a few days. (40;93; 147) Cameron found 
similar results in the rabbit. (34) In the animals which 
died the liver was necrotic and the abdomen was distended 
and filled with foul smelling gas and spore forming bacilli 
and lecithinase, which has been identified with the alpha 
toxin of Clostridium Perfringens type A organisms, were 
found throughout the abdominal cavity and within the necrotic 
liver. (177) It seems that ligation of the hepatic artery 
and all its branches lowers the hepatic oxygen content to 
such a degree that anaerobic bacteria are able to prolif¬ 
erate. (148) These animals also deplete their glycogen 
stores and become hypoglycemic in an effort to maintain 
an adequate metabolic state. (34; 40) Interestingly, if 
penicillin is given to these animals for ten days after 
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hepatic artery ligation they do well and do not die. (148;177) 
Presumably, penicillin prevents the anaerobic bacterial 
overgrowth and within the ten day period sufficient arterial 
collateralization of the liver is established so that the 
hepatic oxygen content can be maintained at a high enough 
level to prevent anaerobic bacterial proliferation once the 
penicillin is stopped. This is further supported by the fact 
that ligation of the hepatic artery and its branches in 
stages over several weeks permits collateral vessels to 
contribute to the liver's oxygen content so that eventually 
the animal's hepatic artery and all of its branches are 
ligated yet the animal can live. (91) Analogous results 
have been found with ligation of the hepatic artery in man. 
(77) This is all very relevant to my research, for if vaso¬ 
pressin does cause constriction of the hepatic artery it 
would in effect’be a sudden "medical" ligation of the 
artery with the possible fatal results described above. 
The total hepatic blood flow in most mammals is 100- 
130 ml./minute/100 gram of liver. (83) This total hepatic 
blood flow is fairly constant when systemic arterial blood 
pressure is maintained between 60 and 160 mmHg. (79) Below 
60 mmHg the total hepatic blood flow rapidly falls, and a- 
bove 160 mmHg the total flow rapidly increases, but within 
that range the hepatic arterial and portal venous flows are 
able to interact in such a way as to keep the total flow 
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stable under physiologic conditions. The spleen helps to 
keep the hepatic flow stable by compensating for changes 
in mesenteric blood flow; if the spleen is removed the 
hepatic blood flow varies more markedly with changes in 
systemic blood pressure. (79) Interestingly, a PCC>2 greater 
than 56 also has been associated with a total hepatic blood 
flow that is hypersensitive to changes in systemic blood 
pressure. (61) It seems, however, that the liver is "over¬ 
perfused" in the sense that it is able to function normally 
when its total blood flow is reduced by as much as 50%. 
Although BSP removal falls proportionately with progressive 
decline in hepatic blood flow, glucose metabolism and util¬ 
ization by the liver (20) and galactose uptake by the liver 
(94) are both unaffected by total hepatic blood flows as 
low as 50% of normal in man and dogs. As we saw above, 
however, it is necessary for the fall in total hepatic blood 
flow to be secondary to a fall in portal venous flow, since 
the hepatic artery flow is crucial for hepatic oxygenation. 
The status of sphincters within the hepatic vasculature 
is still unclear; man most probably does not have hepatic 
sphincters but the situation is less certain in other 
mammals. (83) Bauer demonstrated thick muscular coats along 
the hepatic vein near its junction with the inferior vena 
cava in dogs and correlated this with a sphincter mechanism 
stimulated by histamine which prevents the outflow of blood 
{ 
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from the liver (8); similar conclusions were reached by 
Walker (189) and Moreno (125), both using the dog as an 
experimental model. Arey demonstrated circular and spiral 
muscles in the tunica media of the central and small sublob- 
ular veins of dog using wax model reconstructions and 
questioned whether their function was one of restricting 
flow or of milking the veins to keep blood moving through 
the liver. (2) In thirty mammals studied only the dog, 
seal and racoon had this muscular arrangement. (2) Deysach 
demonstrated muscular sphincters at the level of the sub- 
lobular vein and Knisely demonstrated them at the sinusoidal 
level. (189) Thus, it seems that the hepatic venous system 
of dogs does have at least the potential for sphincter effects 
at several different places. (68) This difference between 
the dog's hepatic vasculature and man's will need to be 
taken into consideration when trying to apply the results 
from my experiment with dogs to a clinical situation with 
man. 
The hepatic nerve plexus receives fibres from the celiac 
plexus, the vagi, and the right phrenic nerve. (83) The 
vessels are innervated by both alpha and beta adrenergic 
fibres as well as parasympathetic cholinergic fibres, but 
the most potent effect on the vessels is that of the alpha 
adrenergic fibres. (72;83) Graded electrical stimulation 
of single fibres of the hepatic plexus leads to a graded 
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response of vasoconstriction in the hepatic artery imply¬ 
ing that each fibre controls the vasculature of only a small 
part of the liver. (29) Stimulation of the entire hepatic 
plexus lead to a marked decrease in hepatic artery flow 
with an increase in hepatic artery pressure (27), but as the 
stimulation is maintained the hepatic artery "escapes" via 
autoregulation and within five minutes the hepatic artery 
flow is back to baseline values. (83) It seems that stim¬ 
ulation of the hepatic plexus has little effect on portal 
venous flow although it does increase portal venous pressure. 
(30;83) As would be expected, the in vivo isolated and 
denervated liver lacks most of its vasomotor tone due to 
its loss of predominantly alpha sympathetic stimulation. (24) 
The hepatic artery responds as would be expected to local 
infusions of epinephrine and acetylcholine with vasoconstric¬ 
tion and vasodilatation respectively. (74) Infusion of epi¬ 
nephrine into the portal vein increased the portal venous 
pressure. (81) Finally, Wakim used quartz-rod transillu¬ 
mination to visualize the hepatic sinusoids during hepatic 
plexus stimulation in frogs and rats and noted marked con¬ 
striction of active sinusoids within two seconds of the 
onset of stimulation. (186) Thus, the hepatic plexus can 
play a significant role in controlling hepatic artery blood 
flow and therefore, I was careful to preserve the plexus 
during surgery in order to obtain results which are as 
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accurate and physiologic as possible. 
The gross distribution of the hepatic artery and 
portal vein within the liver was described above but the 
exact relationship between the smaller branches of these 
vessels and the possible existence of intrahepatic shunts 
are two questions which are not as easily answered. It is 
known that in the cirrhotic liver significant amounts of 
blood pass from the hepatic artery to the portal vein 
through dilated sinusoids. (21;153) As early as 1906, Mall 
injected celloidin into the hepatic artery of normal mammal 
livers and recovered the celloidin from the portal vein (118) 
implying the existence of a communication between the arterial 
and venous systems. Furthermore, communications between 
the hepato-portal systems have been visualized at the sinusoidal 
level using quartz-rod transillumination in the amphibian, 
rat and mouse. (18;188) We have already mentioned that 
hepatic artery branches which supply the bile ducts and 
connective tissue empty into the portal vein before it 
reaches the hepatic sinusoids. These anastomoses are less 
than 50 microns in diameter and are of questionable func¬ 
tional significance. (83) Geumei claims to have demonstra¬ 
ted the presence of unidirectional pre-sinusoidal shunts 
from the arterial to the venous system in isolated perfused 
dog livers. He found the sum of hepatic artery and portal 
vein flows during independent perfusions to be greater than 
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their total flow during simultaneous perfusion and claimed 
that during simultaneous perfusion part of the arterial blood 
travels through shunts to the portal vein and impedes the 
venous flow. When he clamped the hepatic vein and perfused 
through the hepatic artery the perfusate appeared so rapidly 
from the portal vein that he felt the shunt had to be pre- 
sinusoidal based on temporal factors. When he perfused 
through the portal vein all of the perfusate appeared in 
the hepatic vein and none was found in the hepatic artery, 
strongly implying that the shunt is uni-directional. Fur¬ 
thermore, when nylidrin was perfused through the hepatic 
artery it effected arterial and venous flow, but when per¬ 
fused through the portal vein it effected only venous flow, 
again implying a uni-directional shunt. Finally, increasing 
arterial perfusion pressure led to an increase in flow in 
all three vessels, but increasing portal venous perfusion 
pressure increased hepatic venous and portal venous flow 
but decreased hepatic artery flow implying that less arterial 
perfusate was able to pass through the arterio-venous shunts. 
(72;73) When Krypton 85 is injected into the portal vein 
and hepatic artery both independently and simultaneously 
the flow through the hepatic artery is always 75% slower 
than the flow through the portal vein and the simultaneous 
washout curve has been found to have either two or three 
exponential components. (16;92) This has been interpreted 
as representing different channels through the hepatic sin- 
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usoids; the fast component represents pure portal vein channels, 
the medium component represents channels where venous and 
arterial flows are mixing, and the third, slow component, 
represents pure hepatic artery channels. (83) Finally, it 
was shown by Cohn that sinusoidal perfusion by the hepatic 
artery is as extensive as perfusion by the portal vein as 
studied in the intact dog. He perfused labelled albumin 
and labelled red blood cells through each vessel and found 
the ratio of Albumin/RBC perfusion time to be the same for 
each vessel. In both cases the transit time of albumin was 
greater than that for the red blood cells implying that the 
albumin distributes itself in a larger space with a lower 
hematocrit, such as the.hepatic sinusoids. If the hepatic 
artery bypassed the sinusoidal space its albumin time would 
equal its red blood cell time. This was not the case; the 
ratio of albumin to RBC time for the portal vein and hepatic 
artery were identical within experimental error. (39) Thus, 
it seems that there are intra-hepatic communications between 
the hepatic arterioles and portal venules either at the sin¬ 
usoidal or pre-sinusoidal level. This is an important point 
as will become apparent as we discuss reciprocal arterial- 
venous flows and autoregulation. 
We have already discussed autoregulation within the 
hepatic artery. Autoregulation is also involved with re¬ 
ciprocal flows between the portal vein and hepatic artery. 
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As early as 1911, Burton-Opitz found that hepatic artery 
flow in the dog increased approximately 15% when portal venous 
flow was shunted away from the liver toward the renal vein. 
(28) Since that time several investigators have shown that 
in both the intact and the isolated liver in mammals (includ¬ 
ing man and the dog) a decrease in portal venous flow and 
pressure is followed by a significant increase in hepatic 
arterial flow, while an increase in portal venous flow and 
pressure is followed by a decrease in hepatic artery flow. 
(23;31;39;41;83;88;99;101;103;156;160;169;175) Similar 
but much less pronounced reactions are seen in the portal 
venous pressure, but not flow, in response to changes of 
flow and pressure in the hepatic artery. (83;169;179) This 
is what is known as reciprocal flow between the hepatic artery 
and portal vein. It has been found that the hepatic artery 
response is less marked and slower in its onset when the 
hepatic plexus is intact. (39) The phenomenon is a local 
response of the hepatic vasculature and is not dependent 
upon the innervation of the liver. (8;39;156) Since it 
supplies only 25% or so of the total hepatic blood flow, 
the hepatic artery cannot completely compensate for the de¬ 
crease in volume of portal venous flow. (23;83) It can, 
however, compensate for the loss of portal vein oxygen con¬ 
tent, and we have already shown that the liver can function 
normally at 50% of baseline portal venous flow(20;94) if 
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its oxygen content is maintained. 
The mechanism for the reciprocal flow between portal 
vein and hepatic artery is not perfectly understood. In 
most other organs of the body autoregulation serves a 
metabolic function in that the accumulation of metabolic 
products leads to a decrease in arterial resistance so that 
arterial flow can increase and wash out the metabolic pro¬ 
ducts. Thus, the metabolic theory of autoregulation is a 
flow dependent one; it implies that an increase in venous 
pressure would lead to decreased flow and an accumulation 
of metabolic products which would then cause a decrease 
in arterial resistance and a secondary increase in arterial 
flow. In the liver, however, increased hepatic venous pres¬ 
sure leads to an increase in hepatic artery resistance with 
a decrease in hepatic artery flow. (83) Therefore, the 
metabolic theory of a^toregulation does not apply to the liver. 
(83) A second possible mechanism is that the decrease in 
portal flow leads to a decrease in volumetric encroachment 
by portal vein radicles on the hepatic artery and as a result 
the hepatic artery is able to increase its flow. (156) 
When one considers, however, the difference in pressures 
between the hepatic artery (@100mmHg) and the portal vein 
(@10mmHg) it becomes hard to imagine the latter exerting 
a volumetric encroachment on the former. (68) A third possible 
mechanism for the autoregulation and reciprocal flow is that 
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the increased arterial or venous pressure causes increased 
capillary filtration with fluid accumulation in the extra- 
vascular space which would increase tissue hydrostatic pressure 
and extrinsically compress the hepatic blood vessels reducing 
their flow. This seems unlikely as the mechanism, however, 
for it would exert a qualitatively identical effect on the 
arterial and venous flows, while we already know that the 
flows in the two systems vary inversely with respect to each 
other. Furthermore, the effect on the portal venous system 
would be greater since it is thin walled, but we know that 
almost all of the articles referred to above found greater 
responses in the arterial system. 
The fourth possible mechanism is the most likely; auto¬ 
regulation and reciprocal flow are probably the result of 
a myogenic response by the terminal hepatic arterioles to 
changes in pressure. We have already established that there 
are either sinusoidal or pre-sinusoidal communications 
between the hepatic arterial and portal venous systems and 
we know that the sinusoidal system feeds into the hepatic 
venous system. Thus, the hepatic artery, portal vein and 
hepatic vein can all communicate via the hepatic sinusoids. 
An increase in the sinusoidal pressure either secondary to 
increased hepatic vein pressure, increased portal vein pressure 
or increased hepatic artery pressure could lead to an in¬ 
crease in the rhythmic activity of the smooth muscle in the 
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hepatic arteriole walls causing vasoconstriction and decreased 
hepatic artery flow. Since the portal vein contributes more 
to sinusoidal flow than the hepatic artery it is consistent 
with this theory that changes in portal venous pressure are 
45 times more effective than changes in arterial pressure 
in affecting hepatic arterial resistance and flow. (88) 
This is also consistent with Nakata's finding that 40% of 
the total pressure gradient across the liver is between the 
portal venules and the central vein; ie. the hepatic sinusoids 
implying that this region is important for pressure changes. 
(126) The myogenic theory of autoregulation is consistent 
with the observed phenomena of arterial-venous reciprocal 
flow in the liver: when pressure increases in either the 
hepatic vein, portal vein or hepatic artery the pressure 
in the hepatic sinusoids is also elevated which elevates 
the pressure in the hepatic arteriole resistance vessels 
causing a myogenic constriction in these vessels. When the 
pressure is reduced in either the hepatic vein, portal vein 
or hepatic artery the sinusoidal pressure would secondarily 
also be decreased as would the pressure in the terminal - 
hepatic arterioles allowing the myogenic response to relax, 
thereby decreasing the hepatic artery's resistance and 
increasing its flow. (88) When the sinusoidal pressure is 
suddenly lowered the hepatic artery has a brief period of 
excess reactive hyperemia which lasts approximately 30 seconds 
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(83) I will refer back to this myogenic mechanism of auto¬ 
regulation when discussing the results from my experiment 
since the theory is crucial in interpreting my data. 
Before discussing angiography I would like to briefly 
discuss the anatomy of the celiac axis and superior mesen¬ 
teric artery, since these are the vessels with which we will 
be dealing. The celiac and superior mesenteric arteries are 
formed from the ventral segmental arteries of the paired 
dorsal aorta which constitute the arterial part of the 
omphalomesenteric arc of the embryonic circulation. These 
ventral segmental arteries are highly irregular in their 
manner of origin which may account for the many anatomical 
variations which occur between the celiac artery and the SMA. 
(115;139) 
In dogs the celiac trunk is 12-15 mm long and arises 
from the anterior abdominal aorta between the upper borders 
of the first and second lumbar vertebrae. It then trifur¬ 
cates into a common hepatic artery, splenic artery and left 
gastric artery. In 20% of animals the left gastric artery 
comes off of the common hepatic artery. (60) The common 
hepatic artery is 3.5-4.1 mm in diameter and moves upwards, 
forwards and to the right from the celiac axis for a total 
of six centimeters to the Porta of the liver where it takes 
a sharp turn forward and to the right, giving off two to 
four proper hepatic arteries to the liver from its convexity 
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and then continues to the right, forwards and downward as the 
gastroduodenal artery. The gastroduodenal artery gives off 
one or two right gastro-epiploic arteries and then termin¬ 
ates in one or two superior pancreatico-duodenal arteries. 
The splenic artery is 2-3 mm in diameter and moves forward 
and to the left from the celiac axis. It then arches down¬ 
ward and forward giving off several branches to the spleen. 
The left gastric artery is 2-3.5 mm in diameter and moves 
upwards, forwards and slightly to the left from the celiac 
axis giving off numerous branches to the upper part of the 
stomach. The right gastric artery is .2-.7mm in diameter 
and usually arises from the gastro-duodenal but occassion- 
ally comes off of a proper hepatic artery. The above data 
is from a study of celiac angiograms in 24 normal dogs. (60) 
A celiac angiogram from one of my experiments is on page A-l. 
In man the hepatic artery, celiac axis and superior 
mesenteric arteries may be quite irregular. In his study 
of 200 human cadavers Michels found that the celiac axis 
and SMA conformed to textbook description in only 55% of 
cases. He describes twenty six collateral pathways to the 
liver. (123) In 175 selective celiac and SMA arteriograms 
in man only 65% had the classical textbook distributions. 
(185) The most common variations include the hepatic 
artery arising from the left gastric artery or the superior 
mesenteric artery;Grant found the right hepatic artery 
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coming off of the superior mesenteric artery in 12% of human 
autopsies. Woodburne found a 14% incidence of the same 
anomaly. (78;191) The celiac artery and SMA arising from 
a common trunk has been found in 1.4% of 853 consecutive 
autopsies. (115) These arterial anomalies increase the 
clinical significance of my results, for if there is in¬ 
deed a danger of reduced hepatic artery blood flow with 
secondary hepatic ischemia during direct infusion of 
vasopressin into the hepatic artery, then not only celiac 
infusions, but also SMA and gastric artery infusions 
would be contraindicated unless the anomalous hepatic 
artery could be identified and the catheter positioned so 
that the vasopressin could be infused distally to the ori¬ 
gin of the hepatic artery. All of this requires time which 
is valuable in a patient who is acutely bleeding and which 
need not be wasted if it could be established that direct 
intra-arterial infusion of vasopressin does not represent 
a threat to hepatic artery blood flow. 
ANGIOGRAPHY 
The principle of infusing radio-opaque dye into vessels 
to delineate vascular lesions has been employed for many 
years in radiology. It was in 1963, however, that Baum and 




demonstration of intra-abdominal bleeding from undetermined 
sites. (129) They created bleeding points in the gastro¬ 
intestinal tract of dogs and then explored several different 
techniques for localizing the bleeding site. The injection 
of 1^31 an£ p32 tagged albumin was no good because the back¬ 
ground count was too high to localize the bleeding site; 
aortography via a midstream injection did not sufficiently 
visualize the smaller arterial branches and involved the 
use of high doses of contrast material; retrograde aortography 
after occlusion of the aorta with a balloon catheter above 
the celiac axis visualized the peripheral branches well but 
was a fairly dangerous procedure; operative segmental arterio< - 
grajphy was time consuming and dangerous requiring at least 
ten intra-operative injections since each arcade needs to 
be examined separately. (10) Percutaneous selective arterio¬ 
graphy via the femoral artery using the Seldinger technique 
of catheter insertion (163) and radio-opaque polythene 
catheters shaped by immersion in hot water as described 
by Odman (136) was found to be an excellent procedure. 
Using this technique Baum and Nusbaum were able to visualize 
lesions bleeding at a rate as slow as 0.5cc/minute; only a 
minimal amount of contrast material was needed. (10;129) 
Vessels as small as 0.2mm in diameter can be readily visu¬ 
alized by this technique. (60) This technique is especially 
valuable considering that in 20% of patients explored for 
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an upper gastro-intestinal bleed and in 70% of patients 
explored for melena the surgeon cannot find a source of 
bleeding; conventional radiology cannot demonstrate a source 
of bleeding in 20-30% of cases. (13) Selective catheteri¬ 
zation is superior to gastroscopy and esophagoscopy in that 
the latter procedures offer the examiner only a limited field 
of vision, and it is superior to conventional radiologic 
techniques in that one cannot be sure that a lesion seen on 
barium enema or upper gastro-intestinal series is actively 
bleeding. (11) Using selective catheterization of the celiac, 
superior mesenteric, and inferipr mesenteric arteries both 
individually and in combination the following bleeding sites 
have been identified in patients by Baum and Nusbaum: Mallory 
Weiss tears, gastric ulcer, duodenal ulcer, arterial-venous 
malformations, splenic rupture, esophageal varices, pancreatic 
carcinoma, hepatic carcinoma, gastric carcinoma, colonic 
carcinoma, pancreatic cysts, occlusive vascular disease, 
pancreatitis, arterial aneurysms, peri-cecal abscess, colonic 
diverticulum, and post operative bleeding from pseudo an¬ 
eurysms at anastamoses. (10;11;12;13;16;131;184) 
I have already discussed the use of■intra-arterial 
infusions of vasopressin to control gastro-intestinal bleed¬ 
ing; in retrospect this seems to be the logical next step 
once the clinician has identified the bleeding site via 
selective angiography. The same catheter that had been 
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used during angiography is used for the infusion of vaso¬ 
pressin; the drug flows into the vessels just as the contrast 
material did and therefore, any bleeding site visualized 
during angiography will be exposed to vasopressin during the 
drug infusion. It has also been hypothesized that small 
blood clots from the tip of the catheter may help to occlude 
the bleeding site. (171) 
Percutaneous selective angiography does entail certain 
risks. In a survey of 11,402 procedures from 204 hospitals 
in the United States there were seven fatalities (0.06%), 
81 serious complications (0.7%) and 325 minor complications 
(3.0%). (105) The fatalities were secondary to: thrombosis 
of the aorta, renal arteries or carotids; passage of the 
catheter through an aortic coarctation; intramural injection 
with aortic rupture; and pulmonary infarct secondary to 
thrombosis of an inadvertantly punctured saphenous vein. 
The serious complications included: arterial thrombosis 
either at the site of puncture or further along the path 
of the catheter; broken catheter tip or guide wire embolus; 
arterial embolization secondary to dislodged atheromatous 
material or due to intimal damage with thrombus formation 
and later embolization; perforation of major vessels with 
large retroperitoneal hematomas; and bowel ileus and 
necrosis. Temporary arterial spasms, asymptomatic local 
hematomas, asymptomatic intramural or subintimal injections, 
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and perforation of major vessels without late sequelae were 
considered minor complications. (.105) Luke reported five 
major complications during 372 procedures, including severe 
arterial embolization necessitating supracondylar amputation, 
dissecting aneurysm, total obstruction of both popliteal 
arteries by atherosclerotic debris and emboli, post angio¬ 
graphy claudication at 100 feet, an orange-sized hematoma 
at the puncture site, and a myocardial infarction in a 
patient with a previously normal EKG. (114) Haut reported 
a complication rate of 1.8% in 1000 procedures, mainly due 
to post catheterization vascular thrombosis. (89) Formanek 
noted thrombus formation (by x-ray) in 54% of diagnostic pro¬ 
cedures and found that the thrombus formation was directly 
proportional to the duration of the catheterization and not 
related to the diameter of the catheter. The thrombi form 
rapidly, being seen in catheterizations as short as fifteen 
minutes; the thrombus forms as a sleeve around the catheter 
and is peeled from the catheter and left in place in the 
artery as the catheter is withdrawn. (65) Other complica¬ 
tions of selective arteriography include catheter migration, 
bowel infarction, cerebral vascular accidents, spinal cord 
paralysis, gall bladder infarction and renal damage. (55) 
Melnick noted that mechanical injection of contrast material 
caused a brisk and forceful extension of the distal cathe¬ 
ter with a forceful return after the injection. The force 
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of this "whip" was proportional to the injection pressure; 
intimal lacerations and sub-intimal hematomas were found 
in dogs at the point of the catheter's whipping impact. (121) 
Thus, selective arteriography is a useful technique, but 
like all medical procedures it does entail certain risks. 
PERTINENT PREVIOUS WORK 
Having provided the groundwork of information required 
to intelligently evaluate and interpret my data, I would 
now like to briefly discuss those experiments which were 
concerned with a question similar to the one with which I 
have dealt; ie., the effect of vasopressin on hepatic artery 
blood flow. 
Heimburger infused vasopressin intravenously into dogs 
and noted a 72% decrease in portal venous blood flow, a 26% 
decrease in portal venous pressure and a 34% decrease in he¬ 
patic vein flow. The changes in portal pressure and flow 
persisted for fifteen to twenty minutes after the vaso¬ 
pressin infusion was stopped, but the initial decrease in 
total hepatic venous flow was followed by a gradual rise in 
flow almost returning to pre-infusion baseline values while 
the infusion of vasopressin was still in progress. Since 
the fall in hepatic venous flow was less than the fall in 
portal venous flow Heimburger postulated that the hepatic 
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artery blood flow had increased during the vasopressin in¬ 
fusion to make up for the difference between the venous flows. 
(90) 
In 1956, Kehne infused vasopressin intravenously into 
dogs and noted a 33% decrease in portal venous pressure. 
Kehne did not discuss the hepatic artery, but in two graphs 
in the article he showed an increase in hepatic artery pres¬ 
sure of approximately 140% of baseline value, which would 
imply a fall in hepatic artery flow during vasopressin 
infusion. (98) 
Shoemaker injected vasopressin into the portal vein of 
dogs and noted a fall in portal venous pressure and flow, 
a rise in systemic arterial blood pressure and a slight in¬ 
crease in hepatic artery resistance. Since the increase in 
systemic blood pressure was much greater than the increase 
in hepatic artery resistance he hypothesized that there 
would be an increase in hepatic artery blood flow during 
vasopressin infusions. (169) 
Drapanas infused vasopressin (10 units over 15 minutes) 
into the external jugular vein of dogs and monitored hepatic 
artery, SMA, and portal vein blood flows with electromagnetic 
flow probes. The blood flow in each of the vessels fell 
during vasopressin infusion. The fall in hepatic artery 
blood flow was not as great as the fall in portal vein blood 
flow, but "a significant (and sustained) reduction in arterial 
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inflow to the liver was noted in all experiments" during 
vasopressin infusion. (53) 
Hanson infused vasopressin intravenously in dogs and 
monitored blood flows with electromagnetic flow probes. 
He noted a 60% decrease in portal venous flow, a 35% ini¬ 
tial decrease in total hepatic blood flow which then 
increased toward baseline values during the infusion 
(analogous to Heimburger's observations), a 60% decrease in 
SMA flow and an initial fall in hepatic artery blood flow 
which was transient, and was followed by an increase in 
hepatic artery blood flow so that at ten minutes into the 
infusion hepatic artery blood flow was 130% of pre-infusion 
baseline flow. This increase in hepatic artery blood flow 
persisted throughout the remainder of the vasopressin in¬ 
fusion. (87) 
Shaldon infused vasopressin intravenously in patients 
with and without porta-caval shunts and noted a 39% decrease 
in portal venous pressure, a 40% decrease in total hepatic 
blood flow, an 87% increase in splanchnic resistance and 
a 77% increase in hepatic arteriolar resistance (as calculated 
from wedged hepatic vein pressure). The increase in hepatic 
arteriolar resistance implies a decrease in hepatic artery 
blood flow. (165) 
Razzak infused vasopressin intravenously in dogs over 
ten minutes and noted an immediate fall in portal vein 
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pressure and hepatic vein blood flow. The hepatic vein blood 
flow began to return toward baseline values less than half 
way through the infusion while the portal venous pressure 
remained low throughout the infusion. Razzak hypothesized 
(as did Heimburger and Hanson) that the return of hepatic 
venous flow toward baseline values was secondary to an in¬ 
crease in hepatic artery blood flow. (149) 
Mahfouz perfused the anatomically isolated in situ 
canine liver with vasopressin through the hepatic artery and 
noted a 25% decrease in hepatic artery blood flow and a 
20% decrease in portal venous blood flow. When he perfused 
through the portal vein there was no change in the hepatic 
artery blood flow and a 78% decrease in the portal venous 
blood flow. (117) 
Cohen infused vasopressin intravenously into cats and 
monitored splenic artery, hepatic artery and SMA blood flows 
sequentially with electromagnetic flow probes. Vasopressin 
caused constriction of the splenic and superior mesenteric 
arteries with a decrease in their respective blood flows. 
However, the blood flow in the hepatic artery increased dur¬ 
ing the vasopressin infusion secondary to hepatic artery 
vasodilatation. (37) 
Ericsson infused vasopressin intravenously in dogs and 
monitored blood flow with isotope labelled microspheres. 
He noted that vasopressin decreased blood flow in the 
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pancreas, duodenum, tongue, lungs, stomach and bowel but 
increased blood flow in the brain, eyes, kidney and hepatic 
artery. Even with marked decreases in the cardiac output 
blood flow to the hepatic artery was fairly constant and did 
not decrease during vasopressin infusions. (62;63) 
Peter infused vasopressin intravenously and monitored 
blood flow with electromagnetic flow probes in dogs. He 
noted a 47.8% decrease in portal venous flow, a 67.8% decrease 
in gastric artery blood flow, a 63.4% decrease in SMA flow 
and "inconsistent" responses in the hepatic artery. In gen¬ 
eral he found an immediate decrease in hepatic artery blood 
flow during vasopressin infusion followed by a gradual 
rise back toward pre-infusion baseline values. In only one 
of five dogs did the hepatic artery blood flow actually in¬ 
crease above baseline value after its initial decrease in 
blood flow during the vasopressin infusion. (142) 
Aronsen performed celiac, SMA and portal vein angio¬ 
grams in dogs before and during intravenous infusions of 
vasopressin. He found that vasopressin caused a vaso¬ 
dilatation of the main branches of the splenic, gastric and 
superior mesenteric arteries with decreased filling and 
marked constriction of their peripheral branches. Only the 
hepatic artery responded to vasopressin with an increased 
filling of its main branches as well as its peripheral 
branches. (3) 

Finally, Nylander also infused vasopressin intra¬ 
venously in dogs, monitoring the drug's effects with pre- 
and post-infusion angiograms. His results were similar to 
Aronsen's: the central parts of the splenic, gastric and 
superior mesenteric arteries dilated while their distal 
parts, including the gastroduodenal artery, were markedly 
constricted during vasopressin infusion. The central and 
distal parts of the hepatic artery were all dilated during 
the vasopressin infusion. Not only was the hepatic artery 
dilated, but also the velocity of flow of contrast material 
through it was increased, suggesting a decrease in hepatic 
artery vascular resistance. (135) 
From the above experiments it can be seen that there 
is not 100% agreement on vasopressin's effect on the 
hepatic artery. It seems that the overall effect of vaso¬ 
pressin on the hepatic artery is one of vasodilatation, 
yet several investigators in good experiments have shown 
vasopressin to cause hepatic artery vasoconstriction. It 
should be noted that in all of the above experiments in 
intact animals the vasopressin was infused intravenously. 
To the best of my knowledge no one has directly infused 
vasopressin into the hepatic artery while monitoring the 
hepatic artery blood flow to follow the entire sequence 
of vasopressin's effect in the intact, anesthetized mammal. 
This type of experiment would be useful for two reasons: 

49. 
it would be a simple direct way of seeing exactly what does 
happen when vasopressin comes in contact with the hepatic 
artery, and it would be simulating exactly what happens in 
man during direct intra-celiac infusion of vasopressin to 
see whether or not the fear of hepatic ischemia secondary 
to decreased hepatic artery blood flow during vasopressin 
treatment of acute gastro-intestinal bleeding is justified. 
Greenway, in an excellent review article in 1971 on 
the hepatic vascular bed in which he reviewed 415 references 
concluded that "detailed knowledge of the mechanisms of 
drug action on the hepatic vascular bed is almost non¬ 
existent. Few studies have been adequately controlled 
and little attempt has been made to differentiate direct 
and indirect effects." (83) My review of the literature 
leaves me with the same impression; hopefully my work on 
vasopressin's effect on the hepatic artery will help to clear 




The intra-arterial infusion of 
pitressin into the celiac axis of dogs 
with electromagnetic flow probe moni¬ 
toring of blood flow in the hepatic 
artery, splenic artery and portal vein. 
MATERIALS AND METHODS 
Sixteen adult mongrel dogs of both sexes were used. 
The animals were starved for at least eighteen hours prior 
to surgery but otherwise there were no special pre-surgical 
preparations. 
The following procedures are described in the order 
in which they were performed. 
ANESTHESIA: 
The animals were anesthetized with sodium pentobarbi- 
© 
tol (Nembutal Abbott) at an initial dose of 25 mg/kg given 
as a single intravenous injection. Those animals which 
became light during the experiment were given additional 
intravenous injections of 25 mg of Nembutal at a time, 
titrating the frequency of Nembutal injections with the 
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animal's clinical response as judged by spontaneous move¬ 
ments and whimpers and masseter muscle tone. An intravenous 
line in a brachial vein was kept open with normal saline 
at a rate of 50 cc per hour to allow immediate intravenous 
injection of Nembutal when needed. 
INTUBATION: 
Endotracheal intubation was performed in all animals 
and respirations were controlled by a mechanical ventilator 
at a volume sufficient to maintain normal pulmonary move¬ 
ments and a rate of sixteen breaths per minute. The mechan¬ 
ical ventilator operated on room air; no supplemental 
oxygen was given. 
ELECTROCARDIOGRAM: 
Electrocardiogram needle leads were inserted subcutan¬ 
eously in all four extremities and a standard limb lead was 
recorded via the 350-3200 A ECG pre-amplifier channel of 
a Sanborn recorder. The electrocardiogram was monitored 
throughout the experiment. 
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ARTERIAL PRESSURE RECORDINGS: 
A femoral artery cutdown was performed distal to the 
right inguinal ligament and the right femoral artery was 
isolated and ligated distally with 1-0 silk. A polythene 
160 PE catheter was then threaded into the femoral artery 
until its tip was in the aorta, a distance judged roughly 
by external approximation. The catheter was connected to 
a pressure transducer and the aortic pressure was recorded 
on' the 350-3000 c carrier pre-amplifier channel of the San¬ 
born recorder. The Sanborn was calibrated so that a de¬ 
flection of four large squares represented an arterial 
pressure of 200 mmHg. Systemic arterial blood pressure was 
monitored throughout the experiment; the blood pressure 
catheter was flu-shed with 1 cc of normal saline every fifteen 
minutes to prevent clot formation at the tip of the catheter. 
SELECTIVE CELIAC AXIS CATHETERIZATION: 
A femoral artery cutdown was performed distal to the 
left inguinal ligament and the left femoral artery was i- 
solated and carefully separated from the surrounding tissue, 
ligating all small branches with 5-0 silk. The Seldinger 
technique of catheter replacement was employed to introduce 

the celiac axis catheter into the femoral artery. (163) 
The following equipment was used in this technique: a 
puncture needle with a diamond head stilette; a flexible 
rounded end metal leader, the distal end of which is even 
more flexible than the rest of the leader; an adapter for 
$ 
a syringe; and a Form a cath radio opaque catheter with 
an outside diameter of 0.045 inches. The catheter was pre¬ 
shaped by immersion in hot water followed by rapid cooling 
as described by Odman (136) so that the catheter had the 
general shape of a walking cane with two bends forming the 
distal curve; the first bend, approximately 6 cm. from the 
tip of the catheter formed a 135° angle with the rest of 
the catheter, while the second bend, 1 cm. from the tip 
of the catheter was pointed approximately 170° in the 
opposite direction of the main stem of the catheter. 
The femoral artery was ligated with 1-0 silk distal 
to the intended site of puncture. The puncture needle with 
diamond head stilette in place was then introduced into the 
femoral artery taking care to avoid puncture of the rear 
arterial wall. The diamond head stilette was withdrawn 
one centimeter once in the femoral artery while the needle 
was advanced several centimeters into the arterial lumen. 
A proximal 1-0 silk tie around the femoral artery was used 
to control bleeding as the diamond head stilette was 
withdrawn and the flexible metal leader was introduced 
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through the needle several inches into the femoral artery. 
The needle was then withdrawn and the catheter was threaded 
onto the metal leader into the femoral artery. 
FLUOROSCOPY AND PORTABLE X-RAY: 
Using the Siemens Siremobile 2 image intensifier fluoro- 
scope the catheter was advanced to a point beyond the first 
lumbar vertebrae and was then slowly pulled distally, ro¬ 
tating the catheter as it was pulled until it "flowed" into 
one of the aortic branches. At that point 2 cc. of 60% sodium 
diatrizoate (Hypaque ) were injected into the catheter to 
determine if it was in the celiac axis. If properly posi¬ 
tioned, a portable x-ray was taken with the GE portable 
x-ray machine using a Buckey table to allow more careful 
examination of the celiac axis. A repeat portable x-ray 
was taken after the flow probes were in place to make sure 
that they were on the right vessels. The celiac catheter 
was then secured with 5-0 silk at its entrance into the 
femoral artery and was attached to a 50 cc. glass syringe 
filled with normal saline in a Harvard infusion pump and in¬ 
fused at a rate of approximately 0.05 cc/min. to keep the 
celiac catheter open and prevent clot formation at its tip 




A midline abdominal incision was performed from 
xyphoid to pubis; all bleeding vessels were tied with 
5-0 silk and the abdominal cavity was not explored until 
good hemostasis was obtained. The stomach and duodenum 
were then retracted caudally and toward the animal's 
left exposing the Porta Hepatis. The portal vein was 
carefully cleared of surrounding tissue for a length of 
2 cm. distal to the union of its main tributaries. The 
hepatic artery was also cleared of surrounding tissue 
for an area of 2 cm. approximately midway between the 
celiac axis and the Porta Hepatis. Care was taken to 
avoid damaging small arterial and venous branches and to 
split the nerve fibres of the hepatic plexus longitudinally 
so as not to disturb the physiologic neural effects of the 
hepatic plexus on the hepatic artery. The splenic artery 
was then identified and a 2 cm. area was cleared on one of 
its two main branches just distal to their union into the 
main stem of the splenic artery. The flow probes were 
then placed on their respective vessels. 
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FLOW METERS AND PROBES: 
Five non-cannulating electromagnetic flow probes were 
used with internal diameters of 1.5 mm, 2 mm., 3 mm., 4 mm. 
and 8 mm. In the first eleven dogs studied only one Statham 
Electromagnetic flowmeter M4001 was available, but with the 
final dogs studied there were three M4001 flowmeter power 
units. Each probe was calibrated for at least two of the 
M4001 flowmeter units; each probe had its own magnet current, 
phase control and balance control which differed for each 
meter used but which were easily determined by following 
Statham's directions. To calibrate the flowmeter reading 
with the actual flow in cc/min. passing through the flow 
probe the probe was placed around a vessel segment in a 
beaker of saline; an additional amount of saline was 
allowed to pass through the vessel in a given period of time 
and was measured. In all cases a linear relationship was 
found between flowmeter reading and actual vessel flow in 
cc/min. (see diagram pageA-2 )• Each probe was re-calibrated 
every two weeks. As a further check, in every experiment 
after the probes were placed on their respective vessels 
in the animal the vessels were occluded with umbilical tape 
to make sure that zero flow corresponded with a reading of 
zero on the flowmeter. The flow probes were selected so 
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as to have a diameter slightly smaller than their vessels 
diameter. In that way good contact was maintained between 
the flow probe and the vessel wall. 
Once the flow probes were properly positioned 2 cc. 
of 60% Hypaque were again infused into the celiac catheter 
with fluoroscopic monitoring to make sure that the catheter 
had not fallen out of the celiac axis during the manipulations 
of surgery and probe placement; the catheter was repositioned 
in the celiac axis when necessary. Blood flows in the respec¬ 
tive vessels were monitored for one half hour to allow them 
to stabilize prior to starting the actual experiments. 
VASOPRESSIN INFUSION: 
In all groups vasopressin was administered in the form 
<S> 
of aqueous Pitressin (Parke-Davis) standardized to contain 
20 pressor units/cc. One cc. of pitressin mixed with 9 cc.'s 
of normal saline were infused via the Harvard infusion pump 
into the celiac catheter in all experiments; only the rate 
of infusion differed in the different groups. Immediately 
after the completion of each infusion the celiac axis was 
visualized fluoroscopically with a 2 cc. injection of 60% 
Hypaque to make sure that the celiac catheter had stayed 




In each dog studied 10 cc.'s of normal saline without 
pitressin were infused either before or after the pitressin 
infusion at identical infusion rates for equivalent amounts 
of time while blood flows and systemic blood pressure were 
monitored just as in the actual experiments. Thus, each 
animal served as its own control. 
STATISTICAL ANALYSIS: 
All results were expressed as percent change in flow 
(or pressure) from the pre-infusion baseline value. The 
mean and standard error of the mean were calculated for all 
of the data. Comparisons were made between different groups 
with the T-test for paired observations. A P value less than 
or equal to 0.05 was considered significant. All graphs 
were drawn to show a range of two standard errors above 
and below the mean. 
GROUP I: 
In all experiments in this group the animals received 
one cc. of pitressin (20 pressor units) mixed with nine cc.'s 
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of normal saline infused into the celiac axis at a rate of 
1 cc/min. over 10 minutes (ie., 2 pressor units/minute). 
SUBGROUP I A: 
This subgroup consisted of two dogs. Blood flow in 
the hepatic artery of each dog was monitored continuously. 
Systemic blood pressure was also monitored continuously. 
Portal vein and splenic artery flows were not monitored. 
SUBGROUP I B; 
This subgroup consisted of only one dog. Flow in the 
portal vein was monitored continuously as was systemic 
blood pressure. Hepatic artery and splenic artery blood 
flows were not monitored. 
SUBGROUP I C: 
This subgroup consisted of eight dogs in which fifteen 
separate vasopressin infusions were performed. There was 
a sufficient number of flow probes for the three vessels, 
but only one flowmeter was available. Therefore, flows 
in the three vessels were measured sequentially by switching 
the different probes into the meter in succession and 
resetting the meter for the given probe. With practice 
it was possible to do this quickly and accurately so that 
every 30 seconds the flow in another vessel could be 
recorded; eg. first a value was obtained for hepatic artery 
blood flow, then the portal vein probe was hooked into the 
meter and a value obtained for its flow, then the splenic 
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artery was connected to the meter to determine its flow 
and then the hepatic artery was hooked in again and so on. 
The probes were always on their respective vessels, it was 
simply a matter of inserting the wires from each probe into 
the flowmeter in sequence. 
GROUP II: 
These experiments were performed several weeks after 
the experiments in group I. At this time there was a suffi¬ 
cient number of flowmeters as well as flow probes, so that 
the flows in the three vessels could be monitored continu¬ 
ously and simultaneously in all the experiments in group II. 
SUBGROUP II A: 
This subgroup consisted of five dogs (the same dogs 
as subgroup II B) with a total of six pitressin infusions. 
One cc. of pitressin (20 pressor units) mixed with nine 
cc.’s of normal saline were infused into the celiac axis 
at a rate of 1 cc/min. (2 pressor units/min.) over 10 minutes 
in each dog. 
SUBGROUP II B: 
This subgroup consisted of five dogs with a total of 
five pitressin infusions. One cc. of pitressin (20 pressor 
units) mixed with nine cc.'s of normal saline were infused 
into the celiac axis at a rate of 0.1 cc/min. (.2 pressor 
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unit/min.) over 60 minutes. 
For a graphic summary of Part I experiments see chart #1 




The vascular response of the hepatic 
artery to vasopressin as studied by celiac 
angiography in man. 
MATERIALS AND METHODS 
Materials consisted of celiac axis arteriograms taken 
before and during celiac axis infusion of pitressin and a 
compass and a ruler for making measurements. 
The celiac angiograms of 10 patients from the West 
Kaven Veterans' Administration Hospital who underwent 
vasopressin infusion to control gastro-intestinal bleeding 
were examined. Vessel diameters of equivalent branches of 
the hepatic artery were measured before and after vasopressin 
infusion. It was attempted to compare the same branch of 
a vessel at a given distance from a constant anatomical 
marker in the pre- and post-vasopressin films. The same was 
done in each case for either the gastroduodenal, splenic, 
or gastric arteries to serve as a comparison with the hepatic 
artery changes. The hepatic artery main stem was measured 
1 cm. distal to the origin of the gastroduodenal artery. 
The second order hepatic branches were measured 1 cm. distal 
to the first branching of the hepatic main stem. The third 
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order hepatic branch diameters were measured 1 cm. distal 
to the branching of the second order vessels. The fourth 
order vessels were measured 1 cm. distal to the branching 
of the third order vessels and the fifth order hepatic 
branches were measured as accurately as possible at a fixed 
distance distal to the fourth order branching. The gastric 
and splenic artery branches were measured in an analogous 
manner to the hepatic artery. The gastroduodenal artery, 
however, with only a few true branches, was analyzed by 
comparing diameter changes at a given distance from its ori¬ 





In both groups I and II the baseline hepatic artery 
blood flow ranged from 27 cc/min. to 220 cc/min. with a 
mean value of 79.9 cc/min.; the baseline portal vein blood 
flow ranged from 62 cc/min. to 355 cc/min. with a mean 
value of 190.2 cc/min.; the baseline splenic artery blood 
flow ranged from 13 cc/min. to 184 cc/min. with a mean value 
of 64.4 cc/min. and the baseline systemic arterial blood 
pressure ranged from 50 mmHg to 157 mrnHg with a mean value 
of 109.6 mmHg. Based on these figures the hepatic artery 
contributed 30% of the total hepatic blood flow while the 
portal vein contributed 70%. 
GROUP I, SUBGROUP A: 
In both dogs the hepatic artery blood flow began to 
rapidly fall after one minute of infusion (which is how long 
it takes the vasopressin to pass through the catheter when 
infused at a rate of 1 cc/min.) from a mean baseline value 
of 44 cc/min. to a mean low value of 13 cc/min. at three 
minutes of infusion. The hepatic blood flow then steadily 
increased reaching a mean maximum flow of 83 cc/min. three 
minutes after the infusion was finished. This maximum 
flow persisted for nine minutes and then gradually returned 
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to baseline value over thirty minutes. The two control 
experiments showed no change in hepatic artery flow greater 
than 5 cc/min. in either direction. (See graph #1, page 
A-4: "Mean hepatic artery blood flow monitored continu¬ 
ously in two dogs during a total of two pitressin infusions 
at a dose of 2 PU/min. for 10 minutes.") 
GROUP I, SUBGROUP B: 
In this dog the portal vein blood flow began to rapidly 
fall two minutes after the pitressin infusion was started 
from a baseline value of 140 cc/min. to a low value of 70 
cc/min. at six minutes of infusion. The portal flow remain¬ 
ed at this low level for six minutes (ie., until 2 minutes 
after the end of the infusion) and then the portal flow 
progressively increased, reaching a value of 136 cc/min. 
40 minutes after the infusion was finished. There was no 
significant change in flow during the saline infusion. 
(See graph #2, page A-5: "Portal vein flow continuously 
monitored in one dog during pitressin infusion at a dose 
of 2 PU/min. for 10 minutes.") 
GROUP I, SUBGROUP C : 
In this subgroup absolute flow values were converted 
to percent change from baseline flow. Data from subgroups 




The hepatic artery was studied in 10 dogs a total of 
17 times during pitressin infusion and 12 times during 
saline infusion. After one minute of pitressin infusion 
the mean hepatic artery blood flow suddenly fell to 68% of 
baseline flow (P=0.00000050; standard error=0.040) reach¬ 
ing a low value of 56% of baseline flow during the third 
minute of infusion (P=0.00000355; standard error=0.066). 
The mean hepatic artery blood flow then progressively increased, 
reaching a mean value of 130% of baseline flow during the 
eighth minute of infusion (P=0.035; standard error=0.118) 
and 141% (P=0.0046; standard error=0.083) of baseline flow 
during the second minute after the infusion was over. The 
hepatic artery blood flow then gradually returned to baser- 
line value over the next twenty minutes. The saline control 
infusions did not show a significant change in blood flow. 
( See graph #3, page A6 :"Mean hepatic artery blood flow 
monitored sequentially during 17 pitressin infusions at 
a dose of 2 PU/min. for 10 minutes.") 
The portal vein was studied in 9 dogs a total of 16 
times during pitressin infusion and 11 times during saline 
infusion. After Ik minutes of pitressin infusion the por¬ 
tal blood flow began to fall reaching a mean flow of 54% 
of baseline flow (P=0.00000239; standard error=0.052) during 
the sixth minute of infusion. Mean portal vein flow remain¬ 
ed in this low range until three minutes after the infusion 
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was over at which time portal vein flow gradually increased 
being at 93% of baseline value (P=0.076, standard error= 
0.093) thirty minutes after the infusion was stopped. Mean 
portal vein flow did not vary more than 7% from baseline 
value during the saline control infusion. (See graph #4, 
page A-7: "Portal vein flow monitored sequentially during 
16 pitressin infusions at 2 PU/min. for 10 minutes.") 
The splenic artery was studied in 8 dogs a total of 
15 times during pitressin infusion and 10 times during sa¬ 
line control infusion. After one minute of pitressin in¬ 
fusion (at the same time that hepatic artery flow decreased) 
the splenic blood flow began to fall reaching a mean flow 
of 54% of baseline flow (P=0.00000040; standard error=0.055) 
during the sixth minute of infusion. The splenic flow re¬ 
mained at approximately this low level until the infusion 
was over, at which time the splenic flow progressively 
increased being at 92% of baseline flow (P=0.0029; standard 
error=0.040) fifteen minutes after the infusion was finished. 
Splenic artery flow did not vary more than 2% from baseline 
during the saline control infusion. (See graph #5, page A-8: 
"Mean splenic artery blood flow monitored sequentially during 
15 pitressin infusions at a dose of 2 PU/min. for 10 minutes.") 
The mean systemic arterial blood pressure was studied 
in 11 dogs a total of 18 times during pitressin infusion 
and 13 times during saline control infusions. The blood 
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pressure began to increase 1% minutes after the pitressin 
infusion was started (at the same time that portal vein blood 
flow decreased) and reached a maximum value of 136% (P=0.00000Q18; 
standard error=0.046) of baseline pressure during the eighth 
minute of infusion. The blood pressure remained at this 
level until two minutes after the infusion was stopped at 
which time the blood pressure fell, reaching baseline value 
15 minutes after the infusion was over. Mean systemic blood 
pressure did not vary more than 4% during the saline control 
infusion. (See graph #6, page :"Mean systemic arterial 
blood pressure monitored continuously during 18 pitressin 
infusions at a dose of 2 PU/min. for 10 minutes.) 
In analyzing the sequence of events in Group I it seems 
that the hepatic artery and splenic artery reacted immediately 
to pitressin with a dramatic decrease in their respective 
blood flows. Approximately thirty seconds later the systemic 
blood pressure began to increase and the portal vein blood 
flow began to decrease. This was followed by a progressive 
increase in hepatic artery blood flow until a steady state 
was reached of increased hepatic artery blood flow, increased 
systemic arterial blood pressure, decreased portal vein blood 
flow and decreased splenic artery blood flow. These con¬ 
ditions prevailed until several minutes after the infusion 




GROUP II, SUBGROUP A: 
In this subgroup the hepatic artery, splenic artery, 
portal vein and mean systemic blood pressure were monitored 
simultaneously and continuously in five dogs during six 
infusions of pitressin (2 PU/min. for 10 min.) and five sa¬ 
line control infusions. Thus, the conditions were identical 
to those in Group I, but now three flow meters were employed 
so that all three flows could be observed simultaneously 
at any given moment, removing any element of estimation 
or guesswork. 
One minute after the pitressin infusion was started the 
mean hepatic artery blood flow decreased to 74% of baseline 
flow (P=0.0052; standard error=0.113) and the mean splenic 
artery blood flow decreased to 56% -of baseline flow (P=0.0068; 
standard error=0.117). Two minutes after the pitressin 
infusion was started the mean systemic arterial blood pressure 
began to increase and the portal vein blood flow began to 
decrease; at the same time the hepatic artery blood flow 
started to increase while the splenic artery flow continued 
to fall. During the eighth minute of infusion a steady state 
was reached: mean hepatic artery blood flow was 121% of base¬ 
line value (P=0.025; standard error=0.071), mean splenic 
artery blood flow was 39% of baseline value (P=0.00028; 
standard error=0.068) mean portal vein blood flow was 47% 
of baseline value (P=0.0000028; standard error=0.031) and 
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mean systemic blood pressure was 126% of baseline value 
(P=0.0159;standard error=0.074). The hepatic artery blood 
flow remained elevated for five minutes after the infusion 
was finished and then gradually returned to baseline value 
over the next fifteen minutes. (See graph #7, pageA-10: 
"Hepatic artery blood flow monitored continuously during 
6 pitressin infusions at a dose of 2 PU/min. for 10 minutes.") 
The portal vein flow remained depressed until the infusion 
was over and then gradually increased, being at 79% of 
baseline flow thirty minutes after the infusion was over. 
(See graph #8, page Adi:"Portal vein flow monitored contin¬ 
uously during 6 pitressin infusions at a dose of 2PU/min. 
for 10 minutes.) The splenic artery blood flow remained 
depressed until the infusion was over and then gradually 
increased, being at 85% of baseline flow thirty minutes after 
the infusion was* over. (See araph #9, pageA-12 : "Splenic artery 
blood flow monitored continuously during 6 pitressin infusions 
at a dose of 2 PU/min. for 10 minutes.) The mean systemic 
blood pressure remained elevated for two minutes after the 
infusion was finished and then gradually returned to base¬ 
line level over the next ten minutes. (See graph #10, page 
A-13: "Mean arterial systemic blood pressure monitored con¬ 
tinuously during 6 pitressin infusions at a dose of 2 PU/min. 
for 10 minutes.") Blood flows and pressure did not vary 
significantly during the saline control infusions. 
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Thus, the results of Groups I C and II A were analogous, 
confirming that we had not introduced significant error 
in Group I C by evaluating the flows sequentially. To prove 
this statistically the hepatic artery flows during pitressin 
infusion from Group I C and Group II A were analyzed and 
graphed against each other. There was no statistically sig¬ 
nificant difference between the two experiments. (See graph 
#11, page A-14: "Hepatic artery flow monitored continuously 
during 6 pitressin infusions vs. hepatic artery flow monitored 
sequentially during 17 pitressin infusions.") Similar results 
were obtained when the portal vein flows and splenic artery 
flows were compared between the two experiments. (See graph 
#12, page A-15: "Portal vein flow monitored continuously during 
6 pitressin infusions vs. portal vein flow monitored sequen¬ 
tially during 16 pitressin infusions." See graph #13, page 
A-16: "Splenic artery flow monitored continuously during 
6 pitressin infusions vs. splenic artery flow monitored sequen¬ 
tially during 15 pitressin infusions.") 
Since the results from I C and II A were equivalent 
and the experiments were performed under identical conditions 
except for monitoring the flows continuously in II A and 
sequentially in I C, it was decided to combine the results 
to analyze all of the responses to a ten minute infusion 
of 20 pressor units of vasopressin. One minute after the 
pitressin infusion was started the mean hepatic artery blood 
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flow decreased to 69% of baseline flow (P=0.00000024; 
standard error=0.041) and the mean splenic artery blood 
flow decreased to 79% of baseline flow (P=0.00038; standard 
error=0.050). At two minutes after the start of the infusion 
hepatic artery flow was as low as 65% of baseline flow (P= 
0.00000407; standard error=0.062) but by three minutes the 
hepatic artery flow had already started to increase. Mean 
systemic arterial blood pressure began increasing 1% minutes 
after the start of the pitressin infusion and portal vein 
blood flow began falling at the same time. The hepatic artery 
blood flow continued to rise until two minutes after the 
infusion was stopped at which time the mean hepatic artery 
flow was 136% of baseline flow (P=0.00011; standard error= 
0.066). The hepatic flow then gradually returned to base¬ 
line over the next 15 minutes. (See graph #14, page A-17: 
"Hepatic artery .flow during 23 pitressin infusions at a dose 
of 2 PU/min. for 10 minutes.") The portal vein flow went 
as low as 51% of baseline value (P=0.0000002; standard error= 
0.040) and stayed at that level until the infusion was over 
at which time the portal flow began to increase, being at 
89% of baseline flow 30 minutes after the infusion was over. 
(See graph # 15, page A-18: "Portal vein flow during 22 pitressin 
infusions at a dose of 2 PU/min. for 10 minutes.") The splenic 
artery flow fell as low as 50% of baseline flow (P=0.00000044; 
standard error=0.045) and stayed at that level until the in- 
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fusion was over, at which time the splenic artery flow in¬ 
creased, reaching 90% of baseline flow 30 minutes after the 
infusion was stopped. (See graph #16, page A-19: "Splenic 
artery flow during 21 pitressin infusions at a dose of 2 
PU/min. for lOminutes.") The mean systemic blood pressure 
progressively increased after the first lh minutes of in¬ 
fusion, reaching a maximum value of 134% of baseline pressure 
during the eighth minute of infusion (P=0.00000003; standard 
error=0.040). The blood pressure remained at this level 
until the infusion was over at which time it returned to 
baseline values over twenty minutes. (See graph #17, page A-20 
"Mean systemic arterial blood pressure during 24 pitressin 
infusions at a dose of 2 PU/min. for 10 minutes.") 
The results from Groups I C, II A and their combination 
are analogous. The reader is refered to graph #18, page A-21 
to clarify the temporal changes in flow and pressure during 
a ten minute intra-celiac infusion of 20 pressor units of 
vasopressin. 
GROUP II, SUBGROUP B: 
In this group the same six animals which were studied 
in Group II Subgroup A underwent a pitressin infusion at 
the rate of 0.2 Pressor Units/minute for 60 minutes while 
blood flows were monitored continuously. This dosage rate 
more closely approximates the doses used clinically. 
The hepatic artery blood flow began to decrease three 

74. 
minutes after the infusion was started and reached a low 
level of 79% of baseline flow (P=0.010; standard error=0.047) 
during the sixth minute of infusion. The hepatic flow then 
gradually increased, reaching a maximum value of 119% of 
baseline flow (P=0.019; standard error=0.056) during the 
19th minute of infusion. It stayed at this general level 
of flow until the 45th minute of infusion when the hepatic 
artery flow decreased to 111% of baseline flow. It stayed 
at this level until the infusion was over at which time the 
hepatic flow returned to baseline values over 15 minutes. 
(See graph #19, pageA-22 : "Hepatic artery blood flow monitored 
continuously during 5 pitressin infusions at a dose of 0.2 
PU/min. for 60 minutes.") 
The portal vein blood flow began to decrease four minutes 
after the infusion was started, reaching a low level of 40% 
of baseline flow (P=0.000010 ,* standard error=0.052) where 
it approximately remained until the infusion was over, at 
which time the portal vein flow increased reaching a level 
of 81% of baseline value 100 minutes after the infusion was 
stopped. (See graph #20, pageA-23 : "Portal vein blood flow 
monitored continuously during 5 pitressin infusions at a dose 
of 0.2 PU/min. for 60 minutes.") 
The splenic artery blood flow began to fall three minutes 
after the infusion was started (exactly when the hepatic 
artery blood flow began to fall) and reached a low level 

75. 
fluctuating between 32% and 21% of baseline values (P=0.000052; 
standard error=0.072 and P=0.00000010; standard error=0.035 
respectively). The splenic artery flow remained at this 
level until the infusion was stopped at which time the flow 
began to increase, reaching 90% of baseline flow 100 minutes 
after the infusion was over. (See graph #21, page A-24: "Splenic 
artery blood flow monitored continuously during 5 pitressin 
infusions at a dose of 0.2 PU/min. for 60 minutes.") 
The mean systemic arterial blood pressure began to 
increase four minutes after the infusion was started (at the 
same time that the portal vein flow began to fall) and reached 
a maximum value of 121% of baseline pressure (P=0.045; 
standard error=0.075) where it remained until 30 minutes into 
the infusion at which time the blood pressure gradually fell, 
reaching baseline values 10 minutes after the infusion was 
over. (See graph #22, page A-25: "Mean systemic arterial blood 
pressure monitored during 5 pitressin infusions 
at a dose of 0.2 PU/min. for 60 minutes.) 
There was no significant change in blood flows or systemic 
pressure during the saline control infusions. Thus, the 
responses to a lower dose of pitressin infused over a 
prolonged period of time were qualitatively similar to the 
responses seen with the higher dose but shorter duration 
infusions; the changes in vessel flows and systemic pressure, 
however, were not as dramatic in the low dose infusions as 
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they were in the high dose infusions. 
PART II: 
In all ten sets of angiograms studied the hepatic artery 
branches (first order through fifth order) demonstrated either 
no change or an increase in diameter when the vasopressin 
infusion films were compared with the pre-infusion films. 
The gastroduodenal artery showed a marked decrease in 
diameter throughout its length during the vasopressin infu¬ 
sions . 
The splenic artery and gastric artery showed either 
no change or an increase in diameter of their main stem branches 
(first order) in the films taken during the vasopressin 
infusion. The second through fifth order branches of these 
arteries, however, showed either a decrease in diameter or 
were totally absent during the vasopressin infusions. (See 
chart #2, page a-27 & A-28) 
Thus, intra-celiac vasopressin caused a marked constric¬ 
tion in the gastroduodenal artery and the peripheral branches 
of the splenic and gastric arteries, but had little effect 




In this discussion I shall be concerned with the ra¬ 
tionale of my procedures and the implications of my results. 
I will not repeat theories and facts which were already 
discussed in the introduction; the reader will be referred 
back to that section when it seems appropriate. 
The dog was used as my experimental model because 
of its large size and the similarity between its vascular 
anatomy and man's. It should be recalled, however, that 
the dog liver does have muscular hepatic sphincters which 
are not found in man's liver. (2;8;83;125;189) Although 
the function of these sphincters is not clear, it is possible 
that they do play a role in intra-hepatic control of liver 
circulation. 
Although it would have been more applicable to the 
clinical situation in man if the animals were not anesthetized, 
the duration of the procedure and the abdominal surgery 
necessitated the use of sodium pentobarbital anesthesia. 
Pentobarbital (25 mg/kg) in dogs has been found to decrease 
cardiac output, increase hepatic artery blood flow, both 
increase (64) and decrease (62) splanchnic blood flow, increase 
heart rate, decrease mean systemic blood pressure, increase 
arterial PC02 and decrease basal body temperature. (62;64; 
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83;127;145) In all cases, however, the pentobarbital effect 
was transitory; all values returning to normal within thirty 
minutes in spite of continued anesthesia. Since I did not 
begin my vasopressin infusions until approximately two hours 
after the initial anesthetic dose, I feel confident in 
assuming that all of the vascular parameters were stable and 
that the pentobarbital did not distort my experimental results. 
Since it is known that an arterial PCC>2 greater than 
56 is associated with increased splanchnic vascular resistance 
all of the dogs were intubated and respirations were controlled 
at a normal level with a mechanical ventilator to avoid 
respiratory acidosis. (61) Furthermore, since it has been 
found that vasopressin has effects in the hypovolemic dog 
which differ from its actions in the normovolemic animal 
(62) special care was taken during surgery to achieve and 
maintain good hemostasis; in addition the animals were kept 
well hydrated with normal saline. 
Catheterization was performed in the identical manner 
as it is done in man. The Seldinger technique is a rather 
clean procedure with the advantage of being able to use a 
small needle for a given catheter size. (163) The Formacath 
catheter was radio opaque and held its shape at body temper¬ 
ature; the thinner tip made selective celiac catheterization 
that much easier. (136) Hypaque contrast material is trans¬ 
ported rapidly to the kidneys and excreted unchanged in the 
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urine,* with normal renal function elimination is almost 
immediate. (76) This, plus the high dilutional effect of 
the small hypaque bolus in the dog's intravascular volume, 
allowed one to frequently check the position of the catheter 
fluoroscopically without fear of secondary effects from the 
hypaque. No significant complications were encountered during 
catheterization in the sixteen animals studied. 
The anatomy of the celiac axis in the dogs which I 
studied corresponded well with the description given by 
Enge in his angiographic study of the celiac axis in dogs. 
(60) In all sixteen animals the celiac axis trifurcated 
into the common hepatic , left gastric, and splenic arteries; 
no anomalies were noted. An attempt was made during surgery 
to disturb the celiac axis and porta hepatis as little as 
possible; the hepatic plexus was separated longitudinally 
when cleaning the hepatic artery for probe placement so as 
not to distort the physiologic neuro-vascular tone of the 
vessel. No significant changes were noted in blood pressure 
and heart rate either during or after surgery. Hepatic artery 
spasm was noted for approximately fifteen minutes after sur¬ 
gery and flow probe placement. Blood flows, therefore, were 
allowed to stabilize for thirty minutes before pitressin in¬ 
fusion was begun. 
* 
The three vessels studied were chosen for the following 
reasons; flow changes in the hepatic artery, of course, were 
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my primary concern; the portal vein flow was monitored to 
study the interaction of the two afferent vessels of the 
liver to see if there was indeed autoregulation with recipro¬ 
cal flow between the two vessels; the splenic artery was 
monitored to serve as an arterial comparison with the hepatic 
artery. The fact that both the hepatic and splenic arteries 
originate from the same structure during embryonic develop¬ 
ment (139) yet respond differently to vasopressin is quite 
interesting and will be discussed later. 
The electromagnetic flow probes and meters were a rather 
clean and accurate way of monitoring blood flow. The electro¬ 
lytes of blood are charged particles which move between the 
magnetic poles in the flow probe and cut the magnetic lines 
of force at right angles, thereby generating a voltage which 
is registered by the flowmeter. Since the flow of charged 
electrolytes through a blood vessel is really an "endless" 
moving electrolyte solution a steady potential difference 
is recorded on the flowmeter. Blood vessel wails have enough 
electrical conductivity to permit placing the recording e- 
lectrodes around the blood vessel without disturbing the 
intravascular space. Contact between the electrodes and the 
blood vessel is not essential as long as all air is excluded 
from the space surrounding the vessel. The square wave 
flow voltage is proportional to the number of electrolytes 
(volume of blood) passing through the magnetic field; vessel 
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size, position and pulsation do not significantly effect the 
operation of the meter when mean flow is being evaluated. 
When the meter and probe are well calibrated there is a 
linear relationship between flow and flow meter needle de¬ 
flection; my calibration results were consistent with this 
statement. (51;102) It is also possible to leave the flow 
probes in place while the animal recovers to allow continued 
monitoring of blood flow in the intact and awake animal. (146) 
The effects of vasopressin were discussed in the in¬ 
troduction. Pitressin (Parke-Davis) is an aqueous solution 
of' the pressor principle of the posterior pituitary gland, 
substantially free from the oxytocic principle. It is stan¬ 
dardized to contain 20 pressor units/cc. Five units sub¬ 
cutaneously or intramuscularly three times a day are usually 
adequate to give a physiologic response in Diabetes insipidus 
or abdominal distention. (76) The dosages used in my ex¬ 
periments were much greater than this; 20 pressor units intra¬ 
arterially over 10 minutes and 12 pressor units intra-arterially 
over 60 minutes. 
During the 10 minute infusions the catheter position 
was checked immediately after the infusion was over and 
during the sixty minute infusions the catheter postion was 
checked every twenty minutes; the catheter remained in place 
throughout all of the infusions. All three celiac vessels 
received an equal amount of hypaque before the pitressin in- 
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fusion was started; once the infusion was begun, however, 
most of the flow went to the hepatic artery. Thus, I was 
indeed monitoring the direct effect of vasopressin on hepatic 
artery blood flow. 
Results were expressed as percent change from pre-infusion 
values, rather than as absolute values, for the purpose of 
statistical comparison. The absolute amount of flow in a 
given vessel varied significantly from animal to animal, 
depending on animal size, vessel size and blood pressure. 
The change in flow in response to vasopressin, however, was 
analogous in all animals in the vessels studied; this is 
more clearly shown by expressing the results as percent change 
from baseline value. Having each animal serve as its own 
control is an ideal way to control all variables. Conditions 
were identical during the pitressin and saline infusions ex¬ 
cept for the addition of pitressin in the former; any differ¬ 
ence in results between the two groups, therefore, can be 
attributed to the pitressin. 
I found the hepatic artery flow to be 30% of the total 
liver blood flow while the portal vein accounted for 70% 
of the flow during resting baseline measurements. This is 
analogous to the distribution of flow between hepatic artery 
and portal vein found by other investigators. (27;28;73;116; 
160;164) Furthermore, in Groups I C and II A, I found hepatic 
artery flow to be increased 136%, portal vein flow to be 
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decreased 51%, and splenic artery flow to be decreased 50% 
of baseline values. This corresponds well with the percent 
change in flows found by other investigators during vaso¬ 
pressin infusion. (87;90;142) 
In the initial two dogs (Group I A) the hepatic artery 
was studied alone. The results were dramatic and significant; 
allowing pitressin one minute to travel through the celiac 
catheter the hepatic artery responded to the pitressin with 
an immediate fall in blood flow. This primary response, 
however, was transient and was followed by a compensatory 
increase in hepatic artery flow which persisted throughout 
the pitressin infusion and then returned to baseline value. 
The portal vein response in Group I B was also dramatic; 
approximately lh to 2 minutes after the start of the infusion 
(which is enough time for the pitressin to travel through 
the catheter and circulate through the dog's vascular system) 
the portal vein flow fell and remained at a low level until 
the infusion was over. 
It was shown that the results of Group I C with sequen¬ 
tial monitoring of blood flow and Group II A with continuous 
monitoring of blood flow were analagous with no statistically 
significant difference between them. In all cases the hepatic 
artery and portal vein reacted as described above. In addi¬ 
tion, the splenic artery flow fell at the same time that the 
hepatic artery flow fell, remaining at a low level throughout 
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the infusion. The mean systemic blood pressure increased 
at the same time that the portal vein flow fell. 
Thus, in all three vessels studied plus the systemic 
blood pressure the responses to high doses of pitressin 
(2PU/min) over a ten minute period were consistent and 
dramatic. The sequence of events is as follows: Pitressin 
causes a direct vasoconstriction with decreased blood flow 
immediately upon arrival in the hepatic artery and splenic 
artery; as the pitressin becomes systemic over the next thirty 
seconds the systemic blood pressure begins to increase and the 
portal venous flow falls. The hepatic artery responds to the 
fall in venous flow with an increase in its own flow so that 
a steady state is reached of increased hepatic artery flow 
and systemic blood pressure and decreased portal vein and splenic 
artery flows. This state persists throughout the infusion, 
returning to bas'eline value once the infusion is over. The 
changes in flow and blood pressure were statistically sig¬ 
nificant with P values much lower than 0.05. 
The fall in portal vein flow corresponded temporally 
with the rise in systemic blood pressure, and therefore, 
it was most likely due to splanchnic vasoconstriction and 
decreased SMA, IMA, splenic artery and gastric artery blood 
flows. This pre-portal effect of vasopressin on the portal 
vein blood flow has been noted by many other observers. (4;32;36; 
57;83;47;134;142;169;178) Nevertheless, I cannot rule out 
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at least a minor direct effect of vasopressin on the portal 
vein. 
The initial response of the hepatic and splenic arteries 
(decreased blood flow) is consistent with vasopressin's effect 
on the rest of the splanchnic arteries. The hepatic artery, 
however, has a secondary response; as the portal vein flow 
begins to fall the hepatic artery's flow begins to rise. 
This is entirely consistent with the myogenic theory of 
reciprocal flow between the hepatic artery and portal vein 
which was discussed in detail in the introduction (page 33). 
According to this theory, as the portal venous flow decreases 
the pressure within the hepatic sinusoids also decreases; 
the terminal hepatic arterioles which communicate with the 
sinusoids detect this fall in sinusoidal pressure and respond 
with a vasodilatation of the arterial resistance vessels, 
increasing hepatic artery blood flow via this myogenic mech¬ 
anism. The fact that the hepatic artery has the same embryologic 
origin as the other splanchnic arteries, yet responds diff¬ 
erently to vasopressin, is interesting. Even more amazing 
is the angiographic demonstration that the gastroduodenal 
artery, which is actually a branch of the hepatic artery, 
responds to vasopressin with a prolonged vasoconstriction. 
This strongly implies that the autoregulatory mechanism of 
the hepatic artery lies in its distal branches within the 
liver and not in the main stem of the artery which is so 
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closely related ontogenetically to the other splanchnic vessels; 
ie., it supports the sinusoidal-myogenic theory of hepatic 
artery_ autoregulation. 
It should be noted that the increase in hepatic artery 
blood flow to 136% of baseline value will only increase total 
liver blood flow 11%, while the fall in portal vein blood 
flow to 51% of baseline value lowers the total liver blood 
flow 36% (assuming that the hepatic artery contributes 30% 
of total hepatic blood flow and the portal vein contributes 
the rest). Thus, during the pitressin infusion total hepatic 
blood flow is only 75% of its baseline value. We have shown 
in the introduction, however, that the liver is able to func¬ 
tion normally when portal venous flow is decreased by 50%. 
(20;94) It is the oxygen content of the liver, which is 
mainly provided by the hepatic artery, which is critical; 
(48) the increased hepatic artery blood flow during vaso¬ 
pressin infusion adequately maintains the liver's oxygen con¬ 
tent and protects against ischemia. 
My results do help to clarify the confusion created by 
past experiments in this area. I have confirmed the indirect¬ 
ly concluded hypothesis of Keimberger (90) Razzak(149) and 
Shoemaker (169) that hepatic artery flow is increased by 
vasopressin. My results are in total agreement with Hanson's 
work (87) including the percent changes in vessel flows 
(he found a 60% decrease in-portal vein flow and a 130% 
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increase in hepatic artery flow as compared with my values 
of 51% and 136% respectively). Cohen (37), Ericsson (62;63), 
Aronsen (3), and Nylander (135) missed the primary vasocon¬ 
striction of the hepatic artery but did note the secondary 
vasodilatation during vasopressin infusion. They, like all 
other investigators in this field, infused the vasopressin 
intravenously. This only tends to confuse the results, since 
the celiac axis, SMA and IMA all are effected by the vaso¬ 
pressin at the same time. Thus, the portal vein flow begins 
to fall at the same time that the hepatic artery flow starts 
to fall, the former stimulating the myogenic autoregulatory 
response in the terminal hepatic arterioles which then inhibits 
the primary vasoconstrictive effect of vasopressin on the 
hepatic artery. Peter's results were inconsistent (142) and 
Kehne (98), Drapanas (53), Shaldon (165) and Mahfouz (117) 
had results which were contradictory to mine; I am unable 
to explain why this is so. The reader is referred to page 
43 for a more detailed description of these experiments. 
The pitressin infusions in Group II B were more analogous 
to the clinical situation in the treatment of gastro-intestinal 
bleeding; the pitressin dose was 0.2 PU/min. and the infusion 
lasted for one hour, so that each animal received a total 
dose of 12 pressor units of pitressin. The results were 
qualitatively similar to the higher dose infusions of vaso¬ 
pressin, but were much less dramatic. The fall in hepatic 
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artery blood flow preceded the rise in systemic blood pressure 
and consequent fall in portal vein flow. The hepatic artery 
flow then increased to 119% of its baseline value. All flow 
changes were statistically significant with P values less 
than 0.05. Thirty minutes after the infusion started, however 
the systemic blood pressure gradually fell and returned to 
baseline level. Fifteen minutes later the hepatic artery 
blood flow fell to 111% of baseline level and stayed at that 
level until the infusion was over, at which time the hepatic 
artery flow returned to baseline value. Thus, there were two 
major differences between the high dose short duration and 
low dose long duration infusions: the changes in flow and 
pressure were more dramatic in the former, and the systemic 
blood pressure did not remain elevated throughout the entire 
infusion in the latter. Furthermore, there was a slight 
decrease in hepatic artery flow toward the end of the long 
infusion, but this was not significant and hepatic artery 
flow was still significantly greater than baseline flow. 
In trying to explain the return of blood pressure to 
baseline during the long infusions one might hypothesize 
tiring of the vascular muscles with a consequent vasodilata¬ 
tion and decrease in blood pressure. However, the splenic 
artery and portal vein flows remained low during this period 
implying that the splanchnic vessels remained constricted 
and that if there was a vasodilatory effect it was restricted 
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to the peripheral arteries. It must be remembered, hov;ever, 
that these were long procedures taking approximately a total 
of six hours during which time the dog's abdomen was opened. 
Although the abdominal wound was covered with saline soaked 
towels, there was still a significant evaporative cooling 
effect upon the animal which may have contributed to the fall 
in blood pressure. This would also explain why the post¬ 
infusion flow in all three vessels was lower than the pre¬ 
infusion flow in the long infusion experiments. 
The celiac angiograms from patients receiving vasopressin 
infusion revealed peripheral vasoconstriction of all 
branches of the gastric and splenic arteries in addition 
to constriction of the entire gastroduodenal artery while 
the hepatic artery and its branches were unchanged or actually 
slightly vasodilated. This is in agreement with the work done 
by Nylander in dogs (135) and further confirms the unique 
secondary response of the hepatic artery to vasopressin 
infusion. This response in man, being identical to the 
response of the hepatic artery in dogs, is additional support 
in arguing that vasopressin does not represent a threat to 
hepatic artery blood flow. 
There are several additional experiments which might 
be useful to perform in this area. It has been reported 
(62) that hypovolemic dogs respond to vasopressin differently 
than normovolemic dogs. In view of the fact that many patients 
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who would require vasopressin infusions are hypovolemic secon¬ 
dary to their acute gastro-intestinal bleeds it would be ^ 
useful to bleed dogs down to a given blood pressure and then 
repeat the experiments which I have performed. It would 
also be useful to study the effect of intra-celiac infusions 
of vasopressin in the awake dog. This could be done by placing 
the flow probes on their respective vessels and then allow¬ 
ing the animals to recover over several weeks with the probes 
in place. (146) Using animals trained to lie still, and 
local anesthesia for the femoral artery cutdown, one could 
then repeat the experiments which I performed under conditions 
even more similar to those used with man. It would also be 
interesting to repeat the experiments which I performed but 
in addition take liver biopsies to confirm the absence of 
hepatic necrosis. Although the latter experiment would be 
interesting, it is probably not necessary in view of the 
clearcut results from my experiments; hepatic necrosis would 




The effect of intra-celiac infusion of vasopressin on 
hepatic artery blood flow was studied 28 times in 15 dogs 
using non-cannulating electromagnetic flow probes. Portal 
vein flow, splenic artery flow and systemic blood pressure 
were also monitored. Normal saline infusions without vaso¬ 
pressin served as controls in every animal studied. 
Results were consistent in all animals. Initially, 
hepatic artery flow fell to 65 percent of baseline and splenic 
artery flow fell to 50 percent of baseline values. Over 
the next 30 to 60 seconds systemic blood pressure began to 
rise reaching a value of 134 percent of baseline and portal 
vein flow fell to 51 percent of baseline. As portal vein 
flow fell hepatic artery flow increased, reaching a value 
of 136 percent of baseline flow. This state of increased 
hepatic artery blood flow, increased systemic blood pressure, 
decreased portal vein blood flow, and decreased splenic artery 
blood flow persisted throughout the remainder of the vaso¬ 
pressin infusion. All values returned to baseline post¬ 
infusion . 
Angiograms from ten patients who underwent celiac axis 
infusion of vasopressin were also studied. Post vasopressin 
angiograms showed no change (or an actual increase) in hepatic 
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artery diameters while the splenic, gastric, and gastro¬ 
duodenal arteries showed marked peripheral vasoconstric¬ 
tion. 
On the basis of this study as well as evidence from 
the published studies of others, it is concluded that the 
hepatic artery responds to vasopressin with an initial vaso¬ 
constriction and fall in blood flow which is followed by 
vasodilatation and increased hepatic artery flow secondary 
to a myogenic autoregulatory response in the hepatic arter¬ 
ioles. This myogenic response is triggered by the fall in 
hepatic sinusoid pressure which results from the fall in 
portal vein blood flow secondary to pre-portal vasoconstric¬ 
tion caused by vasopressin. The initial fall in hepatic 
artery flow also helps to trigger the myogenic vasodilatation 
The unique secondary increase in hepatic artery blood flow 
enables it to deliver more oxygen to the liver, thereby 
maintaining the liver's oxygen content and protecting it 
against ischemia and necrosis in spite of the decrease in 
portal vein flow. 
In view of the uniform results during infusion of vaso¬ 
pressin in dogs, and in view of the clinical confirmation 
supplied by angiograms of ten patients who underwent celiac 
axis infusion of vasopressin, it is felt that direct celiac 
infusion of vasopressin does not necessarily represent a 
threat to hepatic artery flow. If the clinical situation 

dictates, vasopressin can be infused directly into the main 
celiac axis without causing hepatic ischemia, provided 
compensatory dilatation of the hepatic artery occurs, as 


















Celiac axis angiogram from dog #12 
Diagram of flow probe calibration 
Chart #1: Summary of experiments from Part I 
Graph #1: Mean hepatic arterial blood flow 
monitored continuously during a total of two 
Pitressin infusions at a dose of 2 PU/min. for 
10 minutes. 
Graph #2: Mean portal vein blood flow monitored 
continuously during one Pitressin infusion at 
a dose of 2 PU/min. for 10 minutes * 
Graph #3: Mean hepatic artery blood flow monitored 
sequentially during 17 Pitressin infusions at 
a dose of 2 PU/min. for 10 minutes. 
Graph #4: Mean portal vein blood flow monitored 
sequentially during 16 Pitressin infusions at 
a dose of 2 PU/min. for 10 minutes. 
Graph #5: Mean splenic artery blood flow monitored 
sequentially during 15 Pitressin infusions at 
a dose of 2 PU/min. for 10 minutes. 
Graph #6: Mean systemic arterial blood pressure 
monitored continuously during 18 Pitressin 
infusions at a dose of 2 PU/min. for 10 minutes. 
Graph #7: Mean hepatic artery blood flow monitored 
continuously during 6 Pitressin infusions at 
a dose of 2 PU/min. for 10 minutes. 
Graph #8: Mean portal vein blood flow monitored 
continuously during 6 Pitressin infusions at 
a dose of 2 PU/min. for 10 minutes. 
Graph #9: Mean splenic artery blood flow monitored 
continuously during 6 Pitressin infusions at 
















Graph #10: Mean systemic arterial blood pressure 
monitored continuously during 6 Pitressin infusions 
at a dose of 2 PU/min. for 10 minutes. 
Graph #11: Mean hepatic artery flow monitored 
continuously during 6 Pitressin infusions vs. 
mean hepatic artery flow monitored sequentially 
during 17 Pitressin infusions. 
Graph #12: Mean portal vein flow monitored con¬ 
tinuously during 6 Pitressin infusions vs. mean 
portal vein flow monitored sequentially during 
16 Pitressin infusions. 
Graph #13: Mean splenic artery flow monitored 
continuously during 6 Pitressin infusions vs. 
mean splenic artery flow monitored sequentially 
during 15 Pitressin infusions. 
Graph #14: Hepatic artery blood flow during 23 
Pitressin infusions at a dose of 2 PU/min. for 
10 minutes (Group I C plus II A). 
Graph #15: Portal vein blood flow during 22 
Pitressin infusions at a dose of 2 PU/min. for 
10 minutes (Group I C plus II A ). 
Graph #16: Splenic artery blood flow during 21 
Pitressin infusions at a dose of 2 PU/min. for 
10 minutes (Group I C plus II A). 
Graph #17: Mean systemic arterial blood pressure 
during 24 Pitressin infusions at a dose of 
2 PU/min. for 10 minutes (Group I C plus II A). 
Graph #18: Experiment #12: Intra-celiac infusion 
of Pitressin at a dose of 2 PU/min. for 10 minutes. 
Graph #19: Hepatic artery blood flow monitored 
continuously during 5 Pitressin infusions at a 
dose of 0.2 PU/min. for 60 minutes. 
Graph #20: Portal vein blood flow monitored 
continuously during 5 Pitressin infusions at a 
dose of 0.2 PU/min. for 60 minutes. 
Graph #21: Splenic artery blood flow monitored 
continuously during 5 Pitressin infusions at a 




A-25 Graph #22: Mean systemic arterial blood pressure 
monitored continuously during 5 Pitressin infusions 
at a dose of 0.2 PU/min. for 60 minutes. 
A-26 Diagram #2: Diameter measurements - Part II 
A-27; Chart #2: Part II: Vessel diameter changes during 
A-28 intra-celiac Pitressin infusions. 
All graphs show a range of two standard errors 
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